

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM C/A

UNDER THE SECURITIES ACT OF 1933

(Mark one.)

- ☐ Form C: Offering Statement
- ☐ Form C-U: Progress Update
- ☒ Form C/A: Amendment to Offering Statement
 - ☐ Check box if Amendment is material and investors must reconfirm within five business days.
- ☐ Form C-AR: Annual Report
- ☐ Form C-AR/A: Amendment to Annual Report
- ☐ Form C-TR: Termination of Reporting

Name of issuer

DNA ID, Inc.

Legal status of issuer

Form

Corporation

Jurisdiction of Incorporation/Organization

Delaware

Date of organization

October 1, 2018

Physical address of issuer

29 Little West 12th Street, New York, NY 10014

Website of issuer

<https://www.dnaid.co>

Address of counsel to the issuer for copies of notices

BEVILACQUA PLLC
1050 Connecticut Avenue, NW
Suite 500
Washington, DC 20036
Attention: Louis A. Bevilacqua, Esq.
Email: lou@bevilacquaplhc.com

Name of intermediary through which the Offering will be conducted

MicroVenture Marketplace Inc.

CIK number of intermediary

0001478147

SEC file number of intermediary

008-68458

CRD number, if applicable, of intermediary

152513

Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the Offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the Offering, including the amount of referral and any other fees associated with the Offering

The issuer will not owe a cash commission, or any other direct or indirect interest in the issuer, to the intermediary at the conclusion of the offering.

Any other direct or indirect interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest

The issuer will not owe a cash commission, or any other direct or indirect interest in the issuer, to the intermediary at the conclusion of the Offering.

Name of qualified third party "Escrow Agent" which the Offering will utilize

Evolve Bank and Trust Co.

Type of security offered

Crowd Notes

Target number of Securities to be offered

25,000

Price (or method for determining price)

\$1.00

Target offering amount

\$25,000.00

Oversubscriptions accepted:

☒ Yes

☐ No

Oversubscriptions will be allocated:

☐ Pro-rata basis

☐ First-come, first-served basis

☒ Other: At the Company's discretion

Maximum offering amount (if different from target offering amount)

\$107,000.00

Deadline to reach the target offering amount

December 9, 2019

NOTE: If the sum of the investment commitments does not equal or exceed the target offering amount at the Offering deadline, no Securities will be sold in the Offering, investment commitments will be cancelled and committed funds will be returned.

Current number of employees

1

	Most recent fiscal year-end	Prior fiscal year-end
Total Assets	\$25,483.80	\$0.00
Cash & Cash Equivalents	\$18,999.70	\$0.00
Accounts Receivable	\$0.00	\$0.00
Short-term Debt	\$1,449.53	\$0.00
Long-term Debt	\$0.00	\$0.00
Revenues/Sales	\$0.00	\$0.00
Cost of Goods Sold	\$0.00	\$0.00
Taxes Paid	\$0.00	\$0.00
Net Income	-\$1,697.73	\$0.00

The jurisdictions in which the issuer intends to offer the Securities:

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Guam, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virgin Islands, U.S., Virginia, Washington, West Virginia, Wisconsin, Wyoming, American Samoa, and Northern Mariana Islands

November 21, 2019

FORM C/A

Up to \$107,000.00

DNA ID, Inc.



Explanatory Note

DNA ID, Inc. (the "Company") is filing this Amendment to its Form C, which was first filed with the Securities and Exchange Commission on October 9, 2019. This Amendment is filed to add a webinar transcript attached hereto as (Exhibit F).

Crowd Notes

This Form C/A (including the cover page and all exhibits attached hereto, the "Form C/A") is being furnished by DNA ID, Inc., a Delaware Corporation (the "Company," as well as references to "we," "us," or "our"), to prospective investors for the sole purpose of providing certain information about a potential investment in Crowd Notes of the Company (the "Securities"). Investors in Securities are sometimes referred to herein as "Purchasers." The Company intends to raise at least \$25,000.00 and up to \$107,000.00 from Investors in the offering of Securities described in this Form C/A (this "Offering"). The minimum amount of Securities that can be purchased is \$100.00 per Investor (which may be waived by the Company, in its sole and absolute discretion). The offer made hereby is subject to modification, prior sale and withdrawal at any time.

The rights and obligations of the holders of Securities of the Company are set forth below in the section entitled " *The Offering and the Securities--The Securities*". In order to purchase Securities, a prospective investor must complete the subscription process through the Intermediary's platform, which may be accepted or rejected by the Company, in its sole and absolute discretion. The Company has the right to cancel or rescind its offer to sell the Securities at any time and for any reason.

The Offering is being made through MicroVenture Marketplace, Inc. (the "Intermediary"). The Intermediary will not receive a commission, whether direct or indirect, and the issuer will not owe a commission to the Intermediary at the conclusion of the Offering related to the purchase and sale of the Securities.

	Price to Investors	Service Fees and Commissions ⁽¹⁾⁽²⁾	Net Proceeds
Minimum Individual Purchase Amount	\$100.00	\$0.00	\$100.00
Aggregate Minimum Offering Amount	\$25,000.00	\$0.00	\$25,000.00
Aggregate Maximum Offering Amount	\$107,000.00	\$0.00	\$107,000.00

- (1) This excludes fees to Company's advisors, such as attorneys and accountants.
- (2) The issuer will not owe a commission, whether cash or otherwise, to the Intermediary at the conclusion of the Offering.

A crowdfunding investment involves risk. You should not invest any funds in this Offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the Offering, including the merits and risks involved. These Securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any Securities offered or the terms of the Offering, nor does it pass upon the accuracy or completeness of any Offering document or other materials. These Securities are offered under an exemption from registration; however, neither the U.S. Securities and Exchange Commission nor any state securities authority has made an independent determination that these Securities are exempt from registration. The Company filing this Form C/A for an offering in reliance on Section 4(a)(6) of the Securities Act and pursuant to Regulation CF (§ 227.100 et seq.) must file a report with the Commission annually and post the report on its website at <https://www.dnaid.co> no later than 120 days after the end of the company's fiscal year. The Company may terminate its reporting obligations in the future in accordance with Rule 202(b) of Regulation CF (§ 227.202(b)) by 1) being required to file reports under Section 13(a) or Section 15(d) of the Exchange Act of 1934, as amended, 2) filing at least one annual

report pursuant to Regulation CF and having fewer than 300 holders of record, 3) filing annual reports for three years pursuant to Regulation CF and having assets equal to or less than \$10,000,000, 4) the repurchase of all the Securities sold in this Offering by the Company or another party, or 5) the liquidation or dissolution of the Company.

The date of this Form C/A is November 21, 2019.

The Company has certified that all of the following statements are TRUE for the Company in connection with this Offering:

- 1) Is organized under, and subject to, the laws of a State or territory of the United States or the District of Columbia;
- 2) Is not subject to the requirement to file reports pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d));
- 3) Is not an investment company, as defined in section 3 of the Investment Company Act of 1940 (15 U.S.C. 80a-3), or excluded from the definition of investment company by section 3(b) or section 3(c) of that Act (15 U.S.C. 80a-3(b) or 80a-3(c));
- 4) Is not ineligible to offer or sell securities in reliance on section 4(a)(6) of the Securities Act (15 U.S.C. 77d(a)(6)) as a result of a disqualification as specified in § 227.503(a);
- 5) Has filed with the Commission and provided to investors, to the extent required, any ongoing annual reports required by law during the two years immediately preceding the filing of this Form C/A; and
- 6) Has a specific business plan, which is not to engage in a merger or acquisition with an unidentified company or companies.

THERE ARE SIGNIFICANT RISKS AND UNCERTAINTIES ASSOCIATED WITH AN INVESTMENT IN THE COMPANY AND THE SECURITIES. THE SECURITIES OFFERED HEREBY ARE NOT PUBLICLY-TRADED AND ARE SUBJECT TO TRANSFER RESTRICTIONS. THERE IS NO PUBLIC MARKET FOR THE SECURITIES AND ONE MAY NEVER DEVELOP. AN INVESTMENT IN THE COMPANY IS HIGHLY SPECULATIVE. THE SECURITIES SHOULD NOT BE PURCHASED BY ANYONE WHO CANNOT BEAR THE FINANCIAL RISK OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME AND WHO CANNOT AFFORD THE LOSS OF THEIR ENTIRE INVESTMENT. SEE THE SECTION OF THIS FORM C/A ENTITLED "RISK FACTORS."

THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK THAT MAY NOT BE APPROPRIATE FOR ALL INVESTORS.

THIS FORM C/A DOES NOT CONSTITUTE AN OFFER IN ANY JURISDICTION IN WHICH AN OFFER IS NOT PERMITTED.

PRIOR TO CONSUMMATION OF THE PURCHASE AND SALE OF ANY SECURITY THE COMPANY WILL AFFORD PROSPECTIVE INVESTORS AN OPPORTUNITY TO ASK QUESTIONS OF AND RECEIVE ANSWERS FROM THE COMPANY AND ITS MANAGEMENT CONCERNING THE TERMS AND CONDITIONS OF THIS OFFERING AND THE COMPANY. NO SOURCE OTHER THAN THE INTERMEDIARY HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR MAKE ANY REPRESENTATIONS OTHER THAN THOSE CONTAINED IN THIS FORM C/A, AND IF GIVEN OR MADE BY ANY OTHER SUCH PERSON OR ENTITY, SUCH INFORMATION MUST NOT BE RELIED ON AS HAVING BEEN AUTHORIZED BY THE COMPANY.

PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE THE CONTENTS OF THIS FORM C/A AS LEGAL, ACCOUNTING OR TAX ADVICE OR AS INFORMATION NECESSARILY APPLICABLE TO EACH PROSPECTIVE INVESTOR'S PARTICULAR FINANCIAL SITUATION. EACH INVESTOR SHOULD CONSULT HIS OR HER OWN FINANCIAL ADVISER, COUNSEL AND ACCOUNTANT AS TO LEGAL, TAX AND RELATED MATTERS CONCERNING HIS OR HER INVESTMENT.

THE SECURITIES OFFERED HEREBY WILL HAVE TRANSFER RESTRICTIONS. NO SECURITIES MAY BE PLEDGED, TRANSFERRED, RESOLD OR OTHERWISE DISPOSED OF BY ANY INVESTOR EXCEPT PURSUANT TO RULE 501 OF REGULATION CF. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

NASAA UNIFORM LEGEND

IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR ENTITY ISSUING THE SECURITIES AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED.

THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

SPECIAL NOTICE TO FOREIGN INVESTORS

IF THE INVESTOR LIVES OUTSIDE THE UNITED STATES, IT IS THE INVESTOR'S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF ANY RELEVANT TERRITORY OR JURISDICTION OUTSIDE THE UNITED STATES IN CONNECTION WITH ANY PURCHASE OF THE SECURITIES, INCLUDING OBTAINING REQUIRED GOVERNMENTAL OR OTHER CONSENTS OR OBSERVING ANY OTHER REQUIRED LEGAL OR OTHER FORMALITIES. THE COMPANY RESERVES THE RIGHT TO DENY THE PURCHASE OF THE SECURITIES BY ANY FOREIGN INVESTOR.

SPECIAL NOTICE TO CANADIAN INVESTORS

IF THE INVESTOR LIVES WITHIN CANADA, IT IS THE INVESTOR'S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF A CANADA, SPECIFICALLY WITH REGARD TO THE TRANSFER AND RESALE OF ANY SECURITIES ACQUIRED IN THIS OFFERING.

NOTICE REGARDING ESCROW AGENT

EVOLVE BANK AND TRUST CO., THE ESCROW AGENT SERVICING THE OFFERING, HAS NOT INVESTIGATED THE DESIRABILITY OR ADVISABILITY OF AN INVESTMENT IN THIS OFFERING OR THE SECURITIES OFFERED HEREIN. THE ESCROW AGENT MAKES NO REPRESENTATIONS, WARRANTIES, ENDORSEMENTS, OR JUDGEMENT ON THE MERITS OF THE OFFERING OR THE SECURITIES OFFERED

HEREIN. THE ESCROW AGENT'S CONNECTION TO THE OFFERING IS SOLELY FOR THE LIMITED PURPOSES OF ACTING AS A SERVICE PROVIDER.

Forward Looking Statement Disclosure

This Form C/A and any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this Form C/A are forward-looking statements. Forward-looking statements give the Company's current reasonable expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "should," "can have," "likely" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

The forward-looking statements contained in this Form C/A and any documents incorporated by reference herein or therein are based on reasonable assumptions the Company has made in light of its industry experience, perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. As you read and consider this Form C/A, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond the Company's control) and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual operating and financial performance and cause its performance to differ materially from the performance anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect or change, the Company's actual operating and financial performance may vary in material respects from the performance projected in these forward-looking statements.

Any forward-looking statement made by the Company in this Form C/A or any documents incorporated by reference herein or therein speaks only as of the date of this Form C/A. Factors or events that could cause our actual operating and financial performance to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

ONGOING REPORTING

The Company will file a report electronically with the Securities & Exchange Commission annually and post the report on its website, no later than 120 days after the end of the company's fiscal year.

Once posted, the annual report may be found on the Company's website at: <https://www.dnaid.co>

The Company must continue to comply with the ongoing reporting requirements until:

- 1) the Company is required to file reports under Section 13(a) or Section 15(d) of the Exchange Act;
- 2) the Company has filed at least three annual reports pursuant to Regulation CF and has total assets that do not exceed \$10,000,000;
- 3) the Company has filed at least one annual report pursuant to Regulation CF and has fewer than 300 holders of record;
- 4) the Company or another party repurchases all of the Securities issued in reliance on Section 4(a)(6) of the Securities Act, including any payment in full of debt securities or any complete redemption of redeemable securities; or
- 5) the Company liquidates or dissolves its business in accordance with state law.

About this Form C/A

You should rely only on the information contained in this Form C/A. We have not authorized anyone to provide you with information different from that contained in this Form C/A. We are offering to sell, and seeking offers to buy the Securities only in jurisdictions where offers and sales are permitted. You should assume that the information contained in this Form C/A is accurate only as of the date of this Form C/A, regardless of the time of delivery of this Form C/A or of any sale of Securities. Our business, financial condition, results of operations, and prospects may have changed since that date.

Statements contained herein as to the content of any agreements or other document are summaries and, therefore, are necessarily selective and incomplete and are qualified in their entirety by the actual agreements or other documents. The Company will provide the opportunity to ask questions of and receive answers from the Company's management concerning terms and conditions of the Offering, the Company or any other relevant matters and any additional reasonable information to any prospective Investor prior to the consummation of the sale of the Securities.

This Form C/A does not purport to contain all of the information that may be required to evaluate the Offering and any recipient hereof should conduct its own independent analysis. The statements of the Company contained herein are based on information believed to be reliable. No warranty can be made as to the accuracy of such information or that circumstances have not changed since the date of this Form C/A. The Company does not expect to update or otherwise revise this Form C/A or other materials supplied herewith. The delivery of this Form C/A at any time does not imply that the information contained herein is correct as of any time subsequent to the date of this Form C/A. This Form C/A is submitted in connection with the Offering described herein and may not be reproduced or used for any other purpose.

SUMMARY

The following summary is qualified in its entirety by more detailed information that may appear elsewhere in this Form C/A and the Exhibits hereto. Each prospective Investor is urged to read this Form C/A and the Exhibits hereto in their entirety.

DNA ID, Inc. (the "Company") is a Delaware Corporation, formed on October 1, 2018.

The Company is located at 29 Little West 12th Street, New York, NY 10014.

The Company's website is <https://www.dnaid.co>.

The information available on or through our website is not a part of this Form C/A. In making an investment decision with respect to our Securities, you should only consider the information contained in this Form C/A.

The Business

The Company designs, manufactures, and markets patient registry software, and sells a variety of related professional services solutions, and applications to patient advocacy organizations.

The Offering

Minimum amount of Crowd Notes being offered	\$25,000 Principal Amount
Total Crowd Notes outstanding after Offering (if minimum amount reached)	\$25,000 Principal Amount
Maximum amount of Crowd Notes	\$107,000 Principal Amount
Total Crowd Notes outstanding after Offering (if maximum amount reached)	\$107,000 Principal Amount
Purchase price per Security	\$1.00
Minimum investment amount per investor	\$100.00
Offering deadline	December 9, 2019
Use of proceeds	See the description of the use of proceeds on page 23 hereof.
Voting Rights	See the description of the voting rights on page 33 hereof.

The price of the Securities has been determined by the Company and does not necessarily bear any relationship to the assets, book value, or potential earnings of the Company or any other recognized criteria or value.

RISK FACTORS

Risks Related to the Company's Business and Industry

We have a limited operating history upon which you can evaluate our performance, and accordingly, our prospects must be considered in light of the risks that any new company encounters.

We were incorporated under the laws of Delaware on October 1, 2018. Accordingly, we have no history upon which an evaluation of our prospects and future performance can be made. Our proposed operations are subject to all business risks associated with a new enterprise. The

likelihood of our creation of a viable business must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the inception of a business, operation in a competitive industry, and the continued development of advertising, promotions, and a corresponding client base. We anticipate that our operating expenses will increase for the near future. There can be no assurances that we will ever operate profitably. You should consider the Company's business, operations and prospects in light of the risks, expenses and challenges faced as an early-stage company.

We may face potential difficulties in obtaining capital.

We may have difficulty raising needed capital in the future as a result of, among other factors, our lack of an approved product and revenues from sales, as well as the inherent business risks associated with our company and present and future market conditions. Our business currently does not generate any sales and future sources of revenue may not be sufficient to meet our future capital requirements. We may require additional funds to execute our business strategy and conduct our operations. If adequate funds are unavailable, we may be required to delay, reduce the scope of or eliminate one or more of our research, development or commercialization programs, product launches or marketing efforts, any of which may materially harm our business, financial condition and results of operations.

The development and commercialization of our products/services is highly competitive.

We face competition with respect to any products that we may seek to develop or commercialize in the future. Our competitors include major companies worldwide. Many of our competitors have significantly greater financial, technical, and human resources than we have, and superior expertise in research and development and marketing approved products/services. Thus, they may be better equipped than us to develop and commercialize products/services. These competitors also compete with us in recruiting and retaining qualified personnel, and acquiring technologies. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Accordingly, our competitors may commercialize products more rapidly or effectively than we are able to, which would adversely affect our competitive position, the likelihood that our products/services will achieve initial market acceptance and our ability to generate meaningful additional revenues from our products.

The use of individually identifiable data by our business, our business associates and third parties is regulated at the state, federal and international levels.

Costs associated with information security – such as investment in technology, the costs of compliance with consumer protection laws and costs resulting from consumer fraud – could cause our business and results of operations to suffer materially. Additionally, the success of our online operations depends upon the secure transmission of confidential information over public networks, including the use of cashless payments. The intentional or negligent actions of employees, business associates or third parties may undermine our security measures. As a result, unauthorized parties may obtain access to our data systems and misappropriate confidential data. There can be no assurance that advances in computer capabilities, new discoveries in the field of cryptography or other developments will prevent the compromise of our customer transaction processing capabilities and personal data. If any such compromise of our security or the security of information residing with our business associates or third parties were to occur, it could have a material adverse effect on our reputation, operating results and financial condition. Any compromise of our data security may materially increase the costs we incur to protect against such breaches and could subject us to additional legal risk.

Through our operations, we collect and store certain personal information that our patient users provide in exchange for compensation.

We may share information about such persons with vendors that assist with certain aspects of our business. Security could be compromised and confidential customer or business information misappropriated. Loss of customer or business information could disrupt our operations, damage our reputation, and expose us to claims from customers, financial institutions, payment card associations and other persons, any of which could have an adverse effect on our business, financial condition, and results of operations. In addition, compliance with tougher privacy and information security laws and standards may result in significant expense due to increased investment in technology and the development of new operational processes.

Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.

We collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, business partners, and personally identifiable information of our customers, in our data centers and on our networks. The secure processing and maintenance of this information is critical to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance, or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and regulatory penalties, disrupt our operations and the services we provide to customers, and damage our reputation, and cause a loss of confidence in our products and services, which could adversely affect our business/operating margins, revenues, and competitive position. The secure processing and maintenance of this information is critical to our operations and business strategy, and we devote significant resources to protecting our information.

The Company's success depends on the experience and skill of the board of directors, its executive officers and key employees.

In particular, the Company is dependent on Craig Calderone who is CEO of the Company. The Company has or intends to enter into employment agreements with Craig Calderone, although there can be no assurance that it will do so or that he will continue to be employed by the Company for a particular period of time. The loss of Craig Calderone, or any member of the board of directors or executive officers, could harm the Company's business, financial condition, cash flow, and results of operations.

Although dependent on certain key personnel, the Company does not have any key man life insurance policies on any such people.

The Company is dependent on Craig Calderone in order to conduct its operations and execute its business plan, however, the Company has not purchased any insurance policies with respect to those individuals in the event of their death or disability. Therefore, if Craig Calderone dies or becomes disabled, the Company will not receive any compensation to assist with such person's absence. The loss of such person could negatively affect the Company and its operations.

The Company has indicated that it has engaged in certain transactions with related persons.

Please see the section of this Memorandum entitled "Transactions with Related Persons and Conflicts of Interest" for further details.

We are subject to income taxes as well as non-income based taxes, such as payroll, sales, use, value-added, net worth, property and goods and services taxes, in both the U.S.

Significant judgment is required in determining our provision for income taxes and other tax liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination may be uncertain. Although we believe that our tax estimates are reasonable: (i) there is no assurance that the final determination of tax audits or tax disputes will not be different from what is reflected in our income tax provisions, expense amounts for non-income based taxes and accruals and (ii) any material differences could have an adverse effect on our financial position and results of operations in the period or periods for which determination is made.

We are not subject to Sarbanes-Oxley regulations and lack the financial controls and safeguards required of public companies.

We do not have the internal infrastructure necessary, and are not required, to complete an attestation about our financial controls that would be required under Section 404 of the Sarbanes-Oxley Act of 2002. There can be no assurance that there are no significant deficiencies or material weaknesses in the quality of our financial controls. We expect to incur additional expenses and diversion of management's time if and when it becomes necessary to perform the system and process evaluation, testing and remediation required in order to comply with the management certification and auditor attestation requirements.

The Securities do not accrue interest or otherwise compensate Investors for the period in which the Company uses proceeds from the Offering.

The Securities will accrue no interest and have no maturity date. Therefore, Investors will not be compensated for the time in which the Company uses the proceeds from the Offering before a possible Equity Financing or Liquidity Event that could result in the conversion of the Security, to the benefit of the Investor.

Privacy laws and regulations could restrict our ability or the ability of our customers to obtain, use or disseminate patient information, or could require us to incur significant additional costs to re-design our products.

State, federal, and foreign laws, such as the Federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), regulate the confidentiality of sensitive personal information and the circumstances under which such information may be released. These and future laws could have an adverse impact on our results of operations. Other health information standards, such as regulations under HIPAA, establish standards regarding electronic health data transmissions and transaction code set rules for specified electronic transactions, for example transactions involving claims submissions to third party payors. These also continue to evolve and are often unclear and difficult to apply. In addition, under the federal Health Information Technology for Economic and Clinical Health Act (HITECH Act), which was passed in 2009, many businesses that were previously only indirectly subject to federal HIPAA privacy and security rules became directly subject to such rules because the businesses serve as "business associates" to our customers. On January 17, 2013, the Office for Civil Rights of the Department of Health and Human Services released a final rule implementing the HITECH Act and making certain other changes to HIPAA privacy and security requirements. Compliance has increased the requirements applicable to some of our businesses. Failure to maintain the confidentiality of sensitive personal information in accordance with the applicable regulatory requirements, or to abide by electronic health data transmission standards, could expose us to breach of contract claims, fines and penalties, costs for remediation and harm to our reputation.

If we are found to have violated laws protecting the privacy or security of patient health information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business.

There are a number of U.S. federal and state laws and foreign laws protecting the privacy and security of individually identifiable health information, or "protected health information" including patient records, and restricting the use and disclosure of that protected health information that we are subject to. In the United States, the U.S. Department of Health and Human Services promulgated health information privacy and security rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and then significantly strengthened and broadened the applicability of HIPAA under the Health Information Technology for Economic and Clinical Health Act (HITECH, together HIPAA). HIPAA applies to health care providers engaging in certain standard transactions electronically; health plans and health care clearing houses. These entities are referred to as "covered entities." Certain HIPAA provisions also apply to "business associates" of covered entities, or third party providers of services to covered entities that involve the use or disclosure of protected health information. HIPAA's privacy rules protect medical records and protected health information in all forms by limiting its use and disclosure, giving individuals the right to access, amend and seek accounting of their own health information and limiting, in some circumstances, the use and disclosure of protected health information to the minimum amount reasonably necessary to accomplish the intended purpose of the use or disclosure. HIPAA's security standards require both covered entities and business associates to implement administrative, physical, and technical security measures to maintain the security of protected health information in electronic form. Covered entities and business associates must conduct initial and ongoing risk assessments to ensure the ongoing effectiveness of security measures and maintain a written information security plan.

Beyond HIPAA, most states have adopted data security laws protecting the personal data of state residents. Personal data subject to protection typically includes name coupled with social security number, state-issued identification number, or financial account number. Most states require specific, technical security measures for the protection of all personal data, including employee data, and impose their own breach notification requirements in the event of a loss of personal data. State data security laws generally overlap and apply simultaneously with HIPAA.

We rely heavily on our technology and intellectual property, but we may be unable to adequately or cost-effectively protect or enforce our intellectual property rights, thereby weakening our competitive position and increasing operating costs.

To protect our rights in our services and technology, we rely on a combination of copyright and trademark laws, patents, trade secrets, confidentiality agreements with employees and third parties, and protective contractual provisions. We also rely on laws pertaining to trademarks and domain names to protect the value of our corporate brands and reputation. Despite our efforts to protect our proprietary rights, unauthorized parties may copy aspects of our services or technology, obtain and use information, marks, or technology that we regard as proprietary, or otherwise violate or infringe our intellectual property rights. In addition, it is possible that others could independently develop substantially equivalent intellectual property. If we do not effectively protect our intellectual property, or if others independently develop substantially equivalent intellectual property, our competitive position could be weakened.

Effectively policing the unauthorized use of our services and technology is time-consuming and costly, and the steps taken by us may not prevent misappropriation of our technology or other proprietary assets. The efforts we have taken to protect our proprietary rights may not be sufficient or effective, and unauthorized parties may copy aspects of our services, use similar marks or

domain names, or obtain and use information, marks, or technology that we regard as proprietary. We may have to litigate to enforce our intellectual property rights, to protect our trade secrets, or to determine the validity and scope of others' proprietary rights, which are sometimes not clear or may change. Litigation can be time consuming and expensive, and the outcome can be difficult to predict.

We must acquire or develop new products, evolve existing ones, address any defects or errors, and adapt to technology change.

Technical developments, client requirements, programming languages, and industry standards change frequently in our markets. As a result, success in current markets and new markets will depend upon our ability to enhance current products, address any product defects or errors, acquire or develop and introduce new products that meet client needs, keep pace with technology changes, respond to competitive products, and achieve market acceptance. Product development requires substantial investments for research, refinement, and testing. We may not have sufficient resources to make necessary product development investments. We may experience technical or other difficulties that will delay or prevent the successful development, introduction, or implementation of new or enhanced products. We may also experience technical or other difficulties in the integration of acquired technologies into our existing platform and applications. Inability to introduce or implement new or enhanced products in a timely manner could result in loss of market share if competitors are able to provide solutions to meet customer needs before we do, give rise to unanticipated expenses related to further development or modification of acquired technologies as a result of integration issues, and adversely affect future performance.

Our failure to deliver high quality server solutions could damage our reputation and diminish demand for our products, and subject us to liability.

Our customers require our products to perform at a high level, contain valuable features, and be extremely reliable. The design of our server solutions is sophisticated and complex, and the process for manufacturing, assembling and testing our server solutions is challenging. Occasionally, our design or manufacturing processes may fail to deliver products of the quality that our customers require. For example, a vendor may provide us with a defective component that failed under certain heavy use applications. As a result, our product would need to be repaired. The vendor may agree to pay for the costs of the repairs, but we may incur costs in connection with the recall and diverted resources from other projects. New flaws or limitations in our products may be detected in the future. Part of our strategy is to bring new products to market quickly, and first-generation products may have a higher likelihood of containing undetected flaws. If our customers discover defects or other performance problems with our products, our customers' businesses, and our reputation, may be damaged. Customers may elect to delay or withhold payment for defective or underperforming products, request remedial action, terminate contracts for untimely delivery, or elect not to order additional products. If we do not properly address customer concerns about our products, our reputation and relationships with our customers may be harmed. In addition, we may be subject to product liability claims for a defective product. Any of the foregoing could have an adverse effect on our business and results of operations.

Industry consolidation may result in increased competition, which could result in a loss of customers or a reduction in revenue.

Some of our competitors have made or may make acquisitions or may enter into partnerships or other strategic relationships to offer more comprehensive services than they individually had offered or achieve greater economies of scale. In addition, new entrants not currently considered to be competitors may enter our market through acquisitions, partnerships or strategic relationships. We expect these trends to continue as companies attempt to strengthen or maintain

their market positions. The potential entrants may have competitive advantages over us, such as greater name recognition, longer operating histories, more varied services and larger marketing budgets, as well as greater financial, technical and other resources. The companies resulting from combinations or that expand or vertically integrate their business to include the market that we address may create more compelling service offerings and may offer greater pricing flexibility than we can or may engage in business practices that make it more difficult for us to compete effectively, including on the basis of price, sales and marketing programs, technology or service functionality. These pressures could result in a substantial loss of our customers or a reduction in our revenue.

Our business could be negatively impacted by cyber security threats, attacks and other disruptions.

Like others in our industry, we continue to face advanced and persistent attacks on our information infrastructure where we manage and store various proprietary information and sensitive/confidential data relating to our operations. These attacks may include sophisticated malware (viruses, worms, and other malicious software programs) and phishing emails that attack our products or otherwise exploit any security vulnerabilities. These intrusions sometimes may be zero-day malware that are difficult to identify because they are not included in the signature set of commercially available antivirus scanning programs. Experienced computer programmers and hackers may be able to penetrate our network security and misappropriate or compromise our confidential information or that of our customers or other third-parties, create system disruptions, or cause shutdowns. Additionally, sophisticated software and applications that we produce or procure from third-parties may contain defects in design or manufacture, including "bugs" and other problems that could unexpectedly interfere with the operation of the information infrastructure. A disruption, infiltration or failure of our information infrastructure systems or any of our data centers as a result of software or hardware malfunctions, computer viruses, cyber attacks, employee theft or misuse, power disruptions, natural disasters or accidents could cause breaches of data security, loss of critical data and performance delays, which in turn could adversely affect our business.

If we do not respond to technological changes or upgrade our websites and technology systems, our growth prospects and results of operations could be adversely affected.

To remain competitive, we may need to continue to enhance and improve the functionality and features of our websites and technology infrastructure. As a result, we will need to continue to improve and expand our hosting and network infrastructure and related software capabilities. These improvements may require greater levels of spending than we have experienced in the past. Without such improvements, our operations might suffer from unanticipated system disruptions, slow application performance or unreliable service levels, any of which could negatively affect our reputation and ability to attract and retain customers and contributors. Furthermore, in order to continue to attract and retain new customers, we are likely to incur expenses in connection with continuously updating and improving our user interface and experience. We may face significant delays in introducing new services, products, and enhancements. If competitors introduce new products and services using new technologies or if new industry standards and practices emerge, our existing websites and our proprietary technology and systems may become obsolete or less competitive, and our business may be harmed. In addition, the expansion and improvement of our systems and infrastructure may require us to commit substantial financial, operational and technical resources, with no assurance that our business will improve.

Risks Related to the Securities

Upon conversion of the Crowd Notes, Purchasers who are not “Major Investors” will grant a proxy to vote their underlying securities to the intermediary or its affiliate, and, thus, will not have the right to vote on any matters coming before the shareholders of the Company for a vote. By granting this proxy you are giving up your right to vote on important matters, including significant corporate actions like mergers, amendments to our certificate of incorporation, a liquidation of our company and the election of our directors.

Upon conversion of the Crowd Notes and by virtue of a provision contained in the Crowd Notes, if you are not a Major Investor, that is, an investor who has purchased at least \$25,000 in principal amount of the Crowd Notes, you will grant a proxy to the intermediary or its affiliate to vote the underlying securities that you will acquire upon conversion on all matters coming before the shareholders for a vote. The intermediary does not have any fiduciary duty to you to vote shares in a manner that is in your best interests. Accordingly, the intermediary may vote its proxy in a manner that may not be in the best interests of you as a security holder. For example, the intermediary may vote the proxy in favor of an amendment to our charter that adversely affects the rights of the holders of your class of securities in order to allow for a new investment to occur where the new investor requires senior rights.

The Crowd Notes will not be freely tradable until one year from the initial purchase date. Although the Crowd Notes may be tradable under federal securities law, state securities regulations may apply and each Purchaser should consult with his or her attorney.

You should be aware of the long-term nature of this investment. There is not now and likely will not be a public market for the Crowd Notes. Because the Crowd Notes have not been registered under the Securities Act or under the securities laws of any state or non-United States jurisdiction, the Crowd Notes have transfer restrictions and cannot be resold in the United States except pursuant to Rule 501 of Regulation CF. It is not currently contemplated that registration under the Securities Act or other securities laws will be effected. Limitations on the transfer of the Crowd Notes may also adversely affect the price that you might be able to obtain for the Crowd Notes in a private sale. Purchasers should be aware of the long-term nature of their investment in the Company. Each Purchaser in this Offering will be required to represent that it is purchasing the Securities for its own account, for investment purposes and not with a view to resale or distribution thereof.

Neither the Offering nor the Securities have been registered under federal or state securities laws, leading to an absence of certain regulation applicable to the Company.

No governmental agency has reviewed or passed upon this Offering, the Company, or any Securities of the Company. The Company also has relied on exemptions from securities registration requirements under applicable state securities laws. Investors in the Company, therefore, will not receive any of the benefits that such registration would otherwise provide. Prospective investors must therefore assess the adequacy of disclosure and the fairness of the terms of this Offering on their own or in conjunction with their personal advisors.

No Guarantee of Return on Investment

There is no assurance that a Purchaser will realize a return on its investment or that it will not lose its entire investment. For this reason, each Purchaser should read the Form C/A and all Exhibits carefully and should consult with its own attorney and business advisor prior to making any investment decision.

When forecasting the hypothetical value of their holdings in different liquidity event scenarios, Investors should consider the overall valuation of the Company in addition to their individual return.

Due to the nature of the discount rate of the Crowd Note, when forecasting the hypothetical value of their holdings in different liquidity event scenarios, Investors should consider the overall valuation of the Company in addition to their individual return. In a liquidity event in which the value of an Investor's stake is determined by the discount method (that being situations where applying the Valuation Cap results in a lower return for such Investor), the Investor's individual return will be the same regardless of the Company's valuation. As an example, a \$1,000-dollar investment in Crowd Safe units of a hypothetical company with a discount of 20% and a valuation cap of \$10 million would result in a \$250 return upon a liquidity event in which the company is valued at either \$5 million or \$10 million. However, Investors should consider that an ownership stake in a higher-valued company is generally preferable to an ownership stake with the same absolute value in a lower-valued company. The higher-valued company will have been assessed by the market to be worth more and will have additional funding with which to pursue its goals and is therefore more likely to produce greater returns to the Investor over the longer term.

A majority of the Company is owned by a small number of owners.

Prior to the Offering the Company's current owners of 20% or more beneficially own 100.0% of the Company. Subject to any fiduciary duties owed to our other owners or investors under Delaware law, these owners may be able to exercise significant influence over matters requiring owner approval, including the election of directors or managers and approval of significant Company transactions, and will have significant control over the Company's management and policies. Some of these persons may have interests that are different from yours. For example, these owners may support proposals and actions with which you may disagree. The concentration of ownership could delay or prevent a change in control of the Company or otherwise discourage a potential acquirer from attempting to obtain control of the Company, which in turn could reduce the price potential investors are willing to pay for the Company. In addition, these owners could use their voting influence to maintain the Company's existing management, delay or prevent changes in control of the Company, or support or reject other management and board proposals that are subject to owner approval.

You will not have a vote or influence on the management of the Company.

All decisions with respect to the management of the Company will be made exclusively by the officers, directors, managers or employees of the Company. You, as a Purchaser of Crowd Notes, will have no ability to vote on issues of Company management and will not have the right or power to take part in the management of the company and will not be represented on the board of directors or managers of the Company. Accordingly, no person should purchase a Security unless he or she is willing to entrust all aspects of management to the Company.

The Company has the right to extend the Offering deadline.

The Company may extend the Offering deadline beyond what is currently stated herein. This means that your investment may continue to be held in escrow while the Company attempts to raise the Minimum Amount even after the Offering deadline stated herein is reached. Your investment will not be accruing interest during this time and will simply be held until the new Offering deadline is reached without the Company receiving the Minimum Amount, at which time it will be returned to you without interest or deduction, or the Company receives the Minimum Amount, at which time it will be released to the Company to be used as set forth herein. Upon or shortly after release of such funds to the Company, the Securities will be issued and distributed to you.

There is no present market for the Securities, and we have arbitrarily set the price.

We have arbitrarily set the price of the Securities with reference to the general status of the securities market and other relevant factors. The Offering price for the Securities should not be considered an indication of the actual value of the Securities and is not based on our net worth or prior earnings. We cannot assure you that the Securities could be resold by you at the Offering price or at any other price.

Purchasers will be unable to declare the Security in “default” and demand repayment.

Unlike convertible notes and some other securities, the Securities do not have any “default” provisions upon which the Purchasers will be able to demand repayment of their investment. With respect to Purchasers who invest less than \$25,000 in the Securities, the Company has ultimate discretion as to whether or not to convert the Securities upon a future equity financing and such Purchasers have no right to demand such conversion. Only in limited circumstances, such as a liquidity event, may Such Purchasers demand payment and even then, such payments will be limited to the amount of cash available to the Company.

The Company may never elect to convert the Securities or undergo a liquidity event.

The Company may never receive a future equity financing or, with respect to those Purchasers who invest less than \$25,000, elect to convert the Securities upon such future financing. In addition, the Company may never undergo a liquidity event such as a sale of the Company or an IPO. If neither the conversion of the Securities nor a liquidity event occurs, the Purchasers could be left holding the Securities in perpetuity. The Securities have numerous transfer restrictions and will likely be highly illiquid, with no secondary market on which to sell them. The Securities are not equity interests, have no ownership rights, have no rights to the Company’s assets or profits and have no voting rights or ability to direct the Company or its actions.

In addition to the risks listed above, businesses are often subject to risks not foreseen or fully appreciated by the management. It is not possible to foresee all risks that may affect us. Moreover, the Company cannot predict whether the Company will successfully effectuate the Company’s current business plan. Each prospective Purchaser is encouraged to carefully analyze the risks and merits of an investment in the Securities and should take into consideration when making such analysis, among other, the Risk Factors discussed above.

THE SECURITIES OFFERED INVOLVE A HIGH DEGREE OF RISK AND MAY RESULT IN THE LOSS OF YOUR ENTIRE INVESTMENT. ANY PERSON CONSIDERING THE PURCHASE OF THESE SECURITIES SHOULD BE AWARE OF THESE AND OTHER FACTORS SET FORTH IN THIS FORM C/A AND SHOULD CONSULT WITH HIS OR HER LEGAL, TAX AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN THE SECURITIES. THE SECURITIES SHOULD ONLY BE PURCHASED BY PERSONS WHO CAN AFFORD TO LOSE ALL OF THEIR INVESTMENT.

BUSINESS

Description of the Business

The Company designs, manufactures, and markets patient registry software, and sells a variety of related professional services solutions, and applications to patient advocacy organizations.

Business Plan

We are a technology company helping rare disease advocacy groups organize their patient community and healthcare data. We operate throughout the U.S. with one common brand and business model designed to provide clients with the same high level of service. Our business revolves around three core pillars of technology solutions:

1. **Data Collection:** enabling data collection to revolve around putting the patient first. We use passive data collection to facilitate longitudinal studies over time.
2. **Data Analysis:** enabling custom analytic reports based on data collection. Easy to work with APIs and programming interfaces to enable quicker analysis of good, clean data
3. **Data Sharing:** we enable patients to be a part of global research network. Creating a double-opt-in marketplace for patients to unlock their records. Our solutions help clients organize their patients in a more research friendly way, enabled by technology. We bring together our capabilities in business strategy, technology strategy and operations/functional strategy to help advocacy groups shape and execute their research objectives.

For DNA Contributors:

DNA contributors are able to monetize their raw genetic data from 23andMe, Ancestry.com, or MyHeritage by simply uploading their results. Contributors can also connect their Apple Health Kit in order to manage their health data in one place and get rewarded for daily step activity and completed surveys. Once contributors upload their sequenced DNA data, they can:

- *Browse research projects* – contributors can browse research projects and help rare disease researchers accelerate their studies from heart health, autism, sickle cell, diabetes, and many more.
- *Manage what data to share* – contributors have full control over what health data they share. Each project has specific permissions and users can choose to share their gender, ethnicity, height, weight, and other phenotypes in an anonymous, non-identified way.
- *Get Paid* – contributors get paid for helping specific research projects. The more contributors share, the more their data is worth. Once a user shares their data, they can view past transactions and an overview of what data was shared with the researchers on the platform. Payments are made to patients in the form of Ethereum (ETH) through digital wallets directly from researchers.

For Researchers

Researchers can utilize the DNA ID platform to connect with participants, collect applicable sequenced DNA, and utilize already analyzed data and insights on the platform. Researchers can choose between a Basic, Standard, or Advanced subscription. Subscriptions include:

1. *Basic:* includes user authentication, web survey collection, unlimited questions, and unlimited responses.
2. *Standard:* includes all basic functionality and genomic connection, data collection via web, iOS, or Android, and automated data analysis.
3. *Advanced:* includes all standard functionality and health records connection, data export and sharing, and marketplace access.

History of the Business

The Company's Products and/or Services

Product / Service	Description	Current Market
Patient Registry Data Collection	Our data collection efforts revolve around putting the patient first. We use passive data collection for longitudinal studies over time. Connect already sequenced DNA from genomics labs and connect to electronic health records.	Our current market is advocacy groups for rare diseases and patients who have completed DNA tests and have data they would like to monetize or use to help rare disease studies. On the other end, we target researchers who require this data for rare disease research.
Patient Registry Data Analysis	Automated data analysis on a patient population, which simplifies the bioinformatics. We analyze patient data, and help accelerate insights.	Our current market is advocacy groups for rare diseases and patients who have completed DNA tests and have data they would like to monetize or use to help rare disease studies. On the other end, we target researchers who require this data for rare disease research.
Open Access Research Marketplace	We enable patients to share their data with researchers, but we abide by the double-opt-in rule. And we structure our infrastructure so that patients have total control over who sees patient data.	Rare disease researchers and educators.

We are constantly researching and developing new features and functionality, which we think might appeal to our customers.

We offer our product through our online website and through the Apple iOS app store.

Competition

The Company's primary competitors are RDMD, Backpack health, Luna DNA, Nebula Genomics, Invitae, redcap.

The markets in which we operate are becoming competitive. Our products compete against similar products across a range of businesses. In many of the markets and industry segments in which we sell our products, we compete against some legacy providers that position themselves in different ways. We are well positioned in the industry segments and markets in which we operate, gaining

market share in each indication. Product quality, performance, and transparency are also important differentiating factors.

Customer Base

Our customers are advocacy groups in rare diseases in the Southern California region and the New England area.

Intellectual Property

The Company currently does not have any intellectual property under patent or trademark protection.

Governmental/Regulatory Approval and Compliance

The Company is subject to and affected by laws and regulations of U.S. federal, state, and local governmental authorities. Failure to comply with these laws and regulation could subject the Company to administrative and legal proceedings and actions by these various governmental bodies.

Litigation

There are no existing legal suits pending, or to the Company's knowledge, threatened, against the Company.

Other

The Company's principal address is 29 Little West 12th Street, New York, NY 10014.

The Company conducts business in the United States.

Because this Form C/A focuses primarily on information concerning the Company rather than the industry in which the Company operates, potential Purchasers may wish to conduct their own separate investigation of the Company's industry to obtain greater insight in assessing the Company's prospects.

Exhibit B to this Form C/A is a detailed Company summary. Purchasers are encouraged to review Exhibit B carefully to learn more about the business of the Company, its industry and future plans and prospects. **Exhibit B** is incorporated by reference into this Form C/A.

USE OF PROCEEDS

The following table lists the use of proceeds of the Offering if the Minimum Amount and Maximum Amount are raised.

Use of Proceeds	% of Minimum Proceeds Raised	Amount if Minimum Raised	% of Maximum Proceeds Raised	Amount if Maximum Raised
Campaign marketing expenses or related reimbursement	10.00%	\$2,500	2.34%	\$2,500
General Marketing	12.00%	\$3,000	9.35%	\$10,000
Research and Development	0.00%	\$0	9.35%	\$10,000
Future Wages	60.00%	\$15,000	69.63%	\$74,500
General Working Capital	18.00%	\$4,500	9.35%	\$10,000
Total	100.00%	\$25,000	100.00%	\$107,000

*This Use of Proceeds table does not include a \$1,000 fee for legal services related to this Offering.

The Use of Proceeds chart is not inclusive of fees paid for use of the iDisclose Form C/A generation system, payments to financial and legal service providers, and escrow related fees, all of which were incurred in preparation of the campaign and are due in advance or upon the closing of the campaign. The Company will not be paying the Intermediary any commissions or other fees in connection with this Offering.

The Company does have discretion to alter the use of proceeds as set forth above. The Company may alter the use of proceeds under the following circumstances: Company will be able to change use of proceeds based on business needs.

DIRECTORS, OFFICERS, AND EMPLOYEES

Directors

The officers and directors or managers of the Company are listed below along with all positions and offices held at the Company and their principal occupation and employment responsibilities for the past three (3) years and their educational background and qualifications.

Name	Positions & Offices Held at the Company	Principal Occupation & Employment Responsibilities for the Past 3 Years
Craig Calderone	Chief Executive Officer (August 2018 – present) Responsible for managing all operations, product management, and sales.	Senior Sales Engineer, Leanplum (February 2017 – April 2019) Responsible for creating and delivering highly personalized technical sales presentations in conjunction with the sales team. Collaborated closely with the product team to help influence the product roadmap based on the customer's needs.

		<p>Sales Engineer, Chartbeat (January 2016 – February 2017) Responsible for developing relationships, software, and real-time tools to help media companies understand, measure, and monetize attention earned by their content.</p> <p><i>Education:</i> B.A. in Economics, Villanova University</p>
--	--	---

Indemnification

Indemnification is authorized by the Company to directors, officers or controlling persons acting in their professional capacity pursuant to Delaware law. Indemnification includes expenses such as attorney’s fees and, in certain circumstances, judgments, fines, and settlement amounts actually paid or incurred in connection with actual or threatened actions, suits or proceedings involving such person, except in certain circumstances where a person is adjudged to be guilty of gross negligence or willful misconduct, unless a court of competent jurisdiction determines that such indemnification is fair and reasonable under the circumstances.

Employees

The Company currently has 1 employee in New York.

CAPITALIZATION AND OWNERSHIP

Capitalization

The Company has issued the following outstanding Securities:

Type of security	Common Stock
Amount authorized	10,000,000
Amount outstanding	10,000,000
Voting Rights	One vote per share
Anti-Dilution Rights	None
How this Security may limit, dilute or qualify the Notes/Bonds issued pursuant to Regulation CF	Not applicable
Percentage ownership of the Company by the holders of such Securities (assuming conversion prior to the Offering if convertible securities).	100%

Type of security	SAFE (Simple Agreement for Future Equity)
Amount outstanding	20,000
Valuation Cap	\$4,000,000
Anti-Dilution Rights	None
How this Security may limit, dilute or qualify the Notes/Bonds issued pursuant to Regulation CF	N/A
Percentage ownership of the Company by the holders of such Securities (assuming conversion prior to the Offering if convertible securities).	N/A
Other provisions	If there is an Equity Financing before the expiration or termination of this instrument, the Company will automatically issue to the Investor either: (1) a number of shares of Standard Preferred Stock equal to the Purchase Amount divided by the price per share of the Standard Preferred Stock, if the pre-money valuation is less than or equal to the Valuation Cap; or (2) a number of shares of Safe Preferred Stock equal to the Purchase Amount divided by the Safe Price, if the pre-money valuation is greater than the Valuation Cap.

Type of security	SAFE (Simple Agreement for Future Equity)
Amount outstanding	20,000
Valuation Cap	\$3,000,000
Discount	20%
Anti-Dilution Rights	None
How this Security may limit, dilute or qualify the Notes/Bonds issued pursuant to Regulation CF	N/A
Percentage ownership of the Company by the holders of such Securities (assuming	N/A

conversion prior to the Offering if convertible securities).	
Other Information	If there is an Equity Financing before the expiration or termination of this instrument, the Company will automatically issue to the Investor either: (1) a number of shares of Standard Preferred Stock equal to the Purchase Amount divided by the price per share of the Standard Preferred Stock, if the pre-money valuation is less than or equal to the Valuation Cap; or (2) a number of shares of Safe Preferred Stock equal to the Purchase Amount divided by the Safe Price, if the pre-money valuation is greater than the Valuation Cap.

Antler Accelerator Program Convertible Note

On August 28, 2019, the Company entered into a Memorandum of Understanding (“MOU”) with the Antler Accelerator Program (the “Program”). Pursuant to the terms of the MOU, the Program would provide the Company with mentorship, investors, advisors and potentially a \$150,000 investment through a convertible note. Not all participants in the accelerator will receive the \$150,000 investment. Upon successful completion of the Program, the Company would then repay \$50,000 of the principal amount of the convertible note in Program fees, and the remaining \$100,000 would convert into 10% ownership of the Company at the Company’s next funding round.

Securities Reserved for Issuance

2,500,000 options for shares of common stock may be granted pursuant to the Company’s Stock Incentive Plan. As of the date of this Form C/A, no options have been granted.

The Company has conducted the following exempt offerings within the past three years:

Date of Offering	Exemption	Securities Offered	Amount Sold	Use of Proceeds
20-Dec-2018	4(a)(2)	SAFE	\$20,000	Used as initial capital for the company to build out its platform
20-Aug-2019	4(a)(2)	SAFE	\$20,000	To help launch the mobile app on the Apple App Store.

The Company currently does not have any debt outstanding.

Ownership

A majority of the Company is owned by Craig Calderone.

Below the beneficial owners of 20% percent or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, are listed along with the amount they own.

Name	Percentage Owned Prior to Offering
Craig Calderone	100.0%

FINANCIAL INFORMATION

Please see the financial information listed on the cover page of this Form C/A and attached hereto in addition to the following information. Financial statements are attached hereto as Exhibit A.

Recent Tax Return Information

Total Income	Taxable Income	Total Tax
\$0.00	\$0.00	\$0.00

Operations

Our primary expenses consist of contractor wages and software subscriptions. Thus far we have launched our app in iOS, generated a paid 30-day proof of concept, and plan to release an Android version of our app by year-end.

The Company does not expect to achieve profitability in the next 12 months and intends to focus on the following goals/milestones:

1. Optimizing for patient/user growth
2. Establishing 3 patient advocacy client partnerships
3. Developing our software more to connect with valuable health data points.

Liquidity and Capital Resources

The Offering proceeds are essential to our operations. We plan to use the proceeds as set forth above under "use of proceeds", which is an indispensable element of our business strategy. The Offering proceeds will have a beneficial effect on our liquidity, as we currently have 6 months of runway which will be augmented by the Offering proceeds and used to execute our business strategy.

The Company does not have any additional sources of capital other than the proceeds from the Offering.

Capital Expenditures and Other Obligations

The Company does not intend to make any material capital expenditures in the future.

Material Changes and Other Information

Trends and Uncertainties

After reviewing the above discussion of the steps the Company intends to take, potential Purchasers should consider whether achievement of each step within the estimated time frame is realistic in their judgment. Potential Purchasers should also assess the consequences to the Company of any delays in taking these steps and whether the Company will need additional financing to accomplish them.

The financial statements are an important part of this Form C/A and should be reviewed in their entirety. The financial statements of the Company are attached hereto as Exhibit A.

THE OFFERING AND THE SECURITIES

The Offering

The Company is offering up to 107,000 of Crowd Notes for up to \$107,000.00. The Company is attempting to raise a minimum amount of \$25,000.00 in this Offering (the "Minimum Amount"). The Company must receive commitments from investors in an amount totaling the Minimum Amount by December 9, 2019 (the "Offering Deadline") in order to receive any funds. If the sum of the investment commitments does not equal or exceed the Minimum Amount by the Offering Deadline, no Securities will be sold in the Offering, investment commitments will be cancelled and committed funds will be returned to potential investors without interest or deductions. The Company has the right to extend the Offering Deadline at its discretion. The Company will accept investments in excess of the Minimum Amount up to \$107,000.00 (the "Maximum Amount") and the additional Securities will be allocated at the Company's discretion.

The price of the Securities does not necessarily bear any relationship to the Company's asset value, net worth, revenues or other established criteria of value, and should not be considered indicative of the actual value of the Securities.

In order to purchase the Securities, you must make a commitment to purchase by completing the Subscription Agreement. Purchaser funds will be held in escrow with Evolve Bank and Trust Co. until the Minimum Amount of investments is reached. Purchasers may cancel an investment commitment until 48 hours prior to the Offering Deadline or the Closing, whichever comes first using the cancellation mechanism provided by the Intermediary. The Company will notify Purchasers when the Minimum Amount has been reached. If the Company reaches the Minimum Amount prior to the Offering Deadline, it may close the Offering at least five (5) days after reaching the Minimum Amount and providing notice to the Purchasers. If any material change (other than reaching the Minimum Amount) occurs related to the Offering prior to the Offering Deadline, the Company will provide notice to Purchasers and receive reconfirmations from Purchasers who have already made commitments. If a Purchaser does not reconfirm his or her investment commitment after a material change is made to the terms of the Offering, the Purchaser's investment commitment will be cancelled and the committed funds will be returned without interest or deductions. If a Purchaser does not cancel an investment commitment before the Minimum Amount is reached, the funds will be released to the Company upon closing of the Offering and the Purchaser will receive the Securities in exchange for his or her investment. Any Purchaser funds received after the initial closing will be released to the Company upon a subsequent closing and the Purchaser will receive Securities via Digital Registry in exchange for his or her investment as soon as practicable thereafter.

Subscription Agreements are not binding on the Company until accepted by the Company, which reserves the right to reject, in whole or in part, in its sole and absolute discretion, any subscription. If the Company rejects all or a portion of any subscription, the applicable prospective Purchaser's funds will be returned without interest or deduction.

The price of the Securities was determined arbitrarily. The minimum amount that a Purchaser may invest in the Offering is \$100.00.

The Offering is being made through MicroVenture Marketplace Inc., the Intermediary. The following two fields below sets forth the compensation being paid in connection with the Offering.

Commission/Fees

The issuer will not owe a commission or any other form of compensation to the Intermediary at the conclusion of the offering.

Shares, Warrants and Other Compensation

The issuer will not owe a commission or any other form of compensation to the Intermediary at the conclusion of the offering.

Transfer Agent and Registrar

The Company will act as transfer agent and registrar for the Securities.

The Securities

We request that you please review our organizational documents and the Crowd Safe instrument in conjunction with the following summary information.

Authorized Capitalization

See 'CAPITALIZATION AND OWNERSHIP' above.

Not Currently Equity Interests

The Securities are not currently equity interests in the Company and can be thought of as the right to receive shares at some point in the future upon the occurrence of certain events.

Valuation Cap

\$3,000,000 or \$4,000,000

Conversion of the Crowd Notes.

Upon the occurrence of a Qualified Equity Financing the Crowd Notes will convert into Conversion Shares pursuant to the following:

- a. If the investor is not a Major Investor, the Crowd Notes will convert into Conversion Shares upon the earlier of (i) the Company's election or (ii) a Corporate Transaction.

- b. If the investor is a Major Investor, the Company will convert the Crowd Notes into Conversion Shares prior to the closing of the Qualified Equity Financing.

“Qualified Equity Financing” shall mean the first sale (or series of related sales) by the Company of its Preferred Shares following the Date of Issuance from which the Company receives gross proceeds of not less than \$1,000,000 (excluding the aggregate amount of securities converted into Preferred Shares in connection with such sale (or series of related sales)).

Conversion Mechanics. Company shall convert the Crowd Notes into Conversion Shares equal to the quotient obtained by dividing the Outstanding Principal by the Conversion Price. The issuance of Conversion Shares pursuant to the conversion of the Crowd Notes shall be upon and subject to the same terms and conditions applicable to the shares sold in the Qualified Equity Financing; provided, however, that if the investor is not a Major Investor, the investor shall receive shares of a Shadow Series with certain limited rights.

“Conversion Shares” shall mean with respect to a conversion of the Crowd Notes, the Company’s Preferred Shares issued in the Qualified Equity Financing.

“Shadow Series” shall mean series of the Company’s Preferred Shares that is identical in all respects to the Preferred Shares issued in the Qualified Equity Financing (e.g., if the Company sells Series A Preferred Shares in the Qualified Equity Financing, the Shadow Series would be Series A-1 Preferred Shares), except that the liquidation preference per share of the Shadow Series shall equal the Conversion Price and the following additional differences:

- i. Shadow Series shareholders shall grant their vote on any matter that is submitted to a vote or for the consent of the shareholders of the Company (except for on matters required by law) by Irrevocable Proxy;
- ii. Shadow Series shareholders shall receive quarterly business updates from the Company through the Platform but will have no additional information or inspection rights (except with respect to such rights which are required by law).

“Conversion Price” with respect to a conversion pursuant a Qualified Equity Financing shall equal:

- i. Investors that purchase the first Fifty-Three Thousand, Five Hundred (53,500) Crowd Notes and thereby fund the first Fifty-Three Thousand, Five Hundred Dollars (\$53,500) will receive Crowd Notes with a conversion provision based on a \$3,000,000 (\$3 million) valuation cap instead of a \$4,000,000 (\$4 million) valuation cap. That means, in connection with equity financing of at least \$1,000,000, the company has the option to convert the Crowd Note into non-voting preferred shares (Conversion Shares) at a price based on the lower of (A) the price per unit paid for Preferred Shares by investors in the Qualified Equity Financing or (B) the price per share based on a \$3,000,000 (\$3 million) valuation cap (instead of \$4 million); or
- ii. the lower of (A) the price paid per share for Preferred Shares by the investors in the Qualified Equity Financing, or (B) the quotient resulting from dividing (1) the \$4 million Valuation Cap by (2) the Fully-Diluted Capitalization immediately prior to the closing of the Qualified Equity Financing.

“Irrevocable Proxy” shall mean the agreement appointing the Platform or an affiliate of the Platform as the sole and exclusive attorney and proxy of the Shadow Series shareholder, with full

power of substitution and re-substitution, to vote and exercise all voting and related rights with respect to all of the securities of the Company that now are or hereafter may be beneficially owned by Shadow Series shareholder.

“Major Investor” shall mean any investor in Crowd Notes in which the Purchase Price is equal to or greater than \$25,000.

“Outstanding Principal” shall mean the total of the Purchase Price.

Corporate Transaction

In the event of a Corporate Transaction, the Company shall notify the investor in writing of the terms of the Corporate Transaction.

- a. If the Corporate Transaction occurs prior to a Qualified Equity Financing, the investor shall receive the higher value received by either:
 - i. Quotient obtained by dividing the product of (1) the Outstanding Principal and the Fully-Diluted Capitalization immediately prior to the closing of the Corporate Transaction by the (2) the Valuation Cap; or
 - ii. Obtaining the Corporate Transaction Payment.
- b. If the Corporate Transaction occurs after a Qualified Equity Financing the Company shall convert the Crowd Notes into Conversion Shares pursuant to Conversion Mechanics described above.

“Corporate Transaction” shall mean:

- i. the closing of the sale, transfer or other disposition of all or substantially all of the Company’s assets,
- ii. the consummation of the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the shareholders of the Company immediately prior to such merger or consolidation continue to hold at least 50% of the voting power of the Company or the surviving or acquiring entity),
- iii. the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of the Company’s securities), of the Company’s securities if, after such closing, such person or group of affiliated persons would hold 50% or more of the outstanding voting shares of the Company (or the surviving or acquiring entity), or
- iv. the IPO, liquidation, dissolution or winding up of the Company; provided, however, that a transaction shall not constitute a Corporate Transaction if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately prior to such transaction.

“Corporate Transaction Payment” shall mean an amount equal to two times (2.0X) the Purchase Price. If there are not enough funds to pay the investors in full, then proceeds from the respective transaction will be distributed with equal priority and pro rata among Purchasers in proportion to their Purchase Price.

Termination

The Crowd Notes will terminate upon the earlier of: (a) a conversion of the entire Purchase Price under the Crowd Notes into Conversion Shares; or (b) the payment of amounts due to the investor pursuant to a Corporate Transaction.

In addition, the Purchaser may not transfer the Securities or any Securities into which they are convertible to any of the Company's competitors, as determined by the Company in good faith.

Furthermore, upon the event of an IPO, the equity interest into which the Securities are converted will be subject to a lock-up period and may not be sold for up to 180 days following such IPO.

Voting and Control

The Securities do not have any voting rights. Further, upon conversion of the Crowd Notes into Conversion Shares, Shadow Series shareholders shall grant their vote on any matter that is submitted to a vote or for the consent of the members of the Company (except for on matters required by law) by Irrevocable Proxy.

The Company does not have any voting agreements in place.

The Company does not have any shareholder/equity holder agreements in place.

Anti-Dilution Rights

The Securities do not have anti-dilution rights.

Restrictions on Transfer

Any Securities sold pursuant to Regulation CF being offered may not be transferred by any Purchaser of such Securities during the one-year holding period beginning when the Securities were issued, unless such Securities were transferred: 1) to the Company, 2) to an accredited investor, as defined by Rule 501(d) of Regulation D of the Securities Act of 1933, as amended, 3) as part of an Offering registered with the SEC or 4) to a member of the family of the Purchaser or the equivalent, to a trust controlled by the Purchaser, to a trust created for the benefit of a family member of the Purchaser or the equivalent, or in connection with the death or divorce of the Purchaser or other similar circumstances. "Member of the family" as used herein means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother/father/daughter/son/sister/brother-in-law, and includes adoptive relationships. Remember that although you may legally be able to transfer the Securities, you may not be able to find another party willing to purchase them.

Other Material Terms

The Company does not have the right to repurchase the Crowd Notes. The investor agrees to take any and all actions determined in good faith by the Company's Manager to be advisable to reorganize the instrument and any shares issued pursuant to the terms of the Crowd Notes into a special purpose vehicle or other entity designed to aggregate the interests of holders of Crowd Notes.

TAX MATTERS

EACH PROSPECTIVE INVESTOR SHOULD CONSULT WITH HIS OR HER OWN TAX AND ERISA ADVISOR AS TO THE PARTICULAR CONSEQUENCES TO THE INVESTOR OF THE PURCHASE, OWNERSHIP AND SALE OF THE INVESTOR'S SECURITIES, AS WELL AS POSSIBLE CHANGES IN THE TAX LAWS.

TO ENSURE COMPLIANCE WITH THE REQUIREMENTS IMPOSED BY THE INTERNAL REVENUE SERVICE, WE INFORM YOU THAT ANY TAX STATEMENT IN THIS FORM C/A CONCERNING UNITED STATES FEDERAL TAXES IS NOT INTENDED OR WRITTEN TO BE USED, AND CANNOT BE USED, BY ANY TAXPAYER FOR THE PURPOSE OF AVOIDING ANY TAX-RELATED PENALTIES UNDER THE UNITED STATES INTERNAL REVENUE CODE. ANY TAX STATEMENT HEREIN CONCERNING UNITED STATES FEDERAL TAXES WAS WRITTEN IN CONNECTION WITH THE MARKETING OR PROMOTION OF THE TRANSACTIONS OR MATTERS TO WHICH THE STATEMENT RELATES. EACH TAXPAYER SHOULD SEEK ADVICE BASED ON THE TAXPAYER'S PARTICULAR CIRCUMSTANCES FROM AN INDEPENDENT TAX ADVISOR.

Potential Investors who are not United States residents are urged to consult their tax advisors regarding the United States federal income tax implications of any investment in the Company, as well as the taxation of such investment by their country of residence. Furthermore, it should be anticipated that distributions from the Company to such foreign investors may be subject to UNITED STATES withholding tax.

EACH POTENTIAL INVESTOR SHOULD CONSULT HIS OR HER OWN TAX ADVISOR CONCERNING THE POSSIBLE IMPACT OF STATE TAXES.

TRANSACTIONS WITH RELATED PERSONS AND CONFLICTS OF INTEREST

Related Person Transactions

From time to time the Company may engage in transactions with related persons. Related persons are defined as any director or officer of the Company; any person who is the beneficial owner of 10 percent or more of the Company's outstanding voting equity securities, calculated on the basis of voting power; any promoter of the Company; any immediate family member of any of the foregoing persons or an entity controlled by any such person or persons.

The Company has conducted the following transactions with related persons:

Related Person/Entity	Joseph Calderone
Relationship to the Company	Immediate family member
Total amount of money involved	\$20,000.00
Benefits or compensation received by related person	Potential investment returns
Benefits or compensation received by Company	Initial capital for business
Description of the transaction	Purchase of DNA ID Simple Agreement for Future Equity (SAFE)

Conflicts of Interest

To the best of our knowledge the Company has not engaged in any transactions or relationships, which may give rise to a conflict of interest with the Company, its operations or its security holders.

OTHER INFORMATION

Bad Actor Disclosure

The Company is not subject to any Bad Actor Disqualifications under any relevant U.S. securities laws.

SIGNATURE

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C/A and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.

The issuer also certifies that the attached financial statements are true and complete in all material respects.

/s/Craig Calderone
(Signature)

Craig Calderone
(Name)

Chief Executive Officer
(Title)

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), this Form C/A has been signed by the following persons in the capacities and on the dates indicated.

/s/Craig Calderone
(Signature)

Craig Calderone
(Name)

Chief Executive Officer
(Title)

11/21/2019
(Date)

I, Craig Calderon, being the founder of dna ID, Inc., a Corporation (the “Company”), hereby certify as of this that:

(i) the accompanying unaudited financial statements of the Company, which comprise the balance sheet as of December 31, 2018 and the related statements of income (deficit), stockholder’s equity and cash flows for the year ended December 31, 2018, and the related notes to said financial statements (collectively, the “Financial Statement”), are true and complete in all material respects; and

(ii) the tax return information of the Company included in this Form C/A reflects accurately the information reported on the tax return for the Company filed for the fiscal year ended December, 31, 2018.

/s/Craig Calderone

(Signature)

Craig Calderone

(Name)

Chief Executive Officer

(Title)

11/21/2019

(Date)

EXHIBITS

Exhibit A	Financial Statements
Exhibit B	Company Summary
Exhibit C	Subscription Agreement
Exhibit D	Crowd Note
Exhibit E	Pitch Deck
Exhibit F	Webinar Transcript

EXHIBIT A
Financial Statements

Balance Sheet

DNA ID

As of December 31, 2019

Account	2018
Assets	
Current Assets	
Cash and Cash Equivalents	
Silicon Valley Checking	18,999.70
Total Cash and Cash Equivalents	18,999.70
Total Current Assets	18,999.70
Long Term Assets	
Intangible Assets	6,484.10
Total Long Term Assets	6,484.10
Total Assets	25,483.80
Liabilities and Equity	
Liabilities	
Current Liabilities	
AMEX CC - 1005	1,449.53
Total Current Liabilities	1,449.53
Total Liabilities	1,449.53
Equity	
Current Year Earnings	(1,697.73)
Equity Contribution - Craig Calderone	5,732.00
Equity Draws - Craig Calderone	0.00
Other Equity	20,000.00
Retained Earnings	0.00
Total Equity	24,034.27
Total Liabilities and Equity	25,483.80

Cash Flow Statement

DNA ID

As of August 31, 2019

	2018
Cash Flows from Operating Activities:	
Net income	(562.95)
Adjustments to reconcile Net income to Net cash provided by operating activities:	
Changes in operating assets and liabilities:	
Prepaid expenses and other operating assets	(1,023.34)
Accounts payable, accrued expenses and other liabilities	(4,414.01)
<i>Net cash provided by operating activities</i>	(6,000.30)
Cash Flows from Investing Activities:	
Capital expenditures	0.00
Investments	0.00
<i>Net cash provided by (used in) investing activities</i>	0.00
Cash Flows from Financing Activities:	
Funding	20,000.00
Contributions (distributions)	5,000.00
<i>Net cash provided by (used in) financing activities</i>	25,000.00
Cash and cash equivalents:	
Net increase (decrease) during period	18,999.70
Cash and cash equivalents at beginning of period	0.00
Cash and cash equivalents at end of period	18,999.70

Income Statement

DNA ID

For the year ended December 31, 2018

Account	Total
Revenue - Client	0.00
Revenue - Test Kit	0.00
Total Income	0.00
Gross Profit	0.00
Advertising & Promotions	0.00
Marketing	380.00
Total Marketing	380.00
Computer & Software Supplies	184.10
Dues & Subscriptions	63.00
Office Supplies	1.04
Phone & Internet	25.99
Postage & Shipping	2.28
Software & SaaS	565.00
Bank & Service Charges	1.25
Total Office Expense	842.66
Legal	205.98
Professional Fee - Accounting & Tax	0.00
Total Professional Fees	205.98
Travel - Ground Transportation	59.56
Travel - Lodging	0.00
Travel - Meals & Entertainment	50.88
Travel - Other	0.00
Total Travel & Entertainment	110.44
Total Operating Expenses	1,539.08
Operating Income	(1,539.08)
Interest Expense	(158.65)
Total Other Income / (Expense)	(158.65)
Net Income	(1,697.73)

EXHIBIT B
Company Summary



MICROVENTURES



Company: DNA ID, Inc.

Market: Computer Software

Product: Community marketplace for genomics research

Company Highlights

- Launched in October 2018 and began generating revenue in June 2019
- Accepted into the Antler Accelerator Program in August 2019
- Completed two successful pilot tests in early 2019
- Partnered with Cure Rare Diseases to set up a patient registry

EXECUTIVE SNAPSHOT

DNA ID was founded in October 2018 and began generating revenue in June 2019. So far in 2019, the company has conducted a pilot program for data analysis and has partnered with Cure Rare Diseases, an organization that forges collaborations with researchers and clinicians to develop customized therapeutics for rare diseases, to set up a patient registry. In August 2019, DNA ID also partnered with Your DNA to connect rare disease patients to genetic researchers in a safe, secure, and more efficient way. The company released its app in the Apple App Store and acquired over 50 new users in August 2019, reaching 320 total users. The company plans to use the proceeds of this raise to hire additional engineers, sales, and business development staff.

PERKS

Investors that purchase the first 53,500 Crowd Notes, and thereby fund the first \$53,500, will receive Crowd Notes with a conversion provision based on a \$3 million valuation cap instead of a \$4 million valuation cap. That means, in connection with equity financing of at least \$1 million, the company has the option to convert the Crowd Note into non-voting preferred shares (Conversion Shares) at a price based on the lower of (A) the price per unit paid for Preferred Shares by investors in the Qualified Equity Financing or (B) the price per share based on a \$3 million valuation cap (instead of \$4 million).

COMPANY SUMMARY

Opportunity

At-home genetic testing has grown in popularity over the past several years. Originally used as a way for individuals and families to learn about their ancestral origins, today's direct-to-consumer (DTC) testing kits are designed to analyze an individual's potential risk of developing or passing on hereditary diseases, potentially adverse genetic conditions, physical health issues, and more. These advancements have helped promote awareness of genetic diseases while giving consumers the opportunity to proactively manage their physical wellbeing.



MICROVENTURES

With DNA ID, people can now monetize their DNA findings from these at-home genetic testing kits while also helping scientists with rare disease research and cures. Rare disease researchers struggle to find patients without the help of a clinician and even with one, can have difficulties filling clinical trials. Due to the small market of rare diseases, funding is scarce for researchers, and there is typically a lack of existing literature and research.¹

DNA ID connects DNA contributors directly to medical researchers using a blockchain-based marketplace for easy collaboration and incentivization. By creating a fair, transparent marketplace to incentivize and reward people for sharing their DNA and health data, DNA ID facilitates direct access to disease-curing studies and research.

Product

DNA ID seeks to help rare disease advocacy groups organize their patient community and healthcare data. The company plans to accomplish this by creating a trusted, open-access data platform utilizing encrypted storage and sharing solutions using blockchain technology. Through the DNA ID patient registry platform, the company is able to provide research with patient-reported outcomes, passive data collection, and genomic and digital health data, helping researchers put together a more complete picture of real-world evidence. The DNA ID platform can be accessed online or through its mobile app, currently available on iOS and scheduled to be released for Android devices in Q4 2019.


For DNA Contributors:

DNA contributors are able to monetize their raw genetic data from 23andMe, Ancestry.com, or MyHeritage by simply uploading their results. Contributors can also connect their Apple Health Kit in order to manage their health data in one place and get rewarded for daily step activity and completed surveys. Once contributors upload their sequenced DNA data, they can:

- *Browse research projects* – contributors can browse research projects and help rare disease researchers accelerate their studies from heart health, autism, sickle cell, diabetes, and many more.
- *Manage what data to share* – contributors have full control over what health data they share. Each project has specific permissions and users can choose to share their gender, ethnicity, height, weight, and other phenotypes in an anonymous, non-identified way.
- *Get Paid* – contributors get paid for helping specific research projects. The more contributors share, the more their data is worth. Once a user shares their data, they can view past transactions and an overview of what data was shared with the researchers on the platform. Payments are made to patients in the form of Ethereum (ETH) through digital wallets directly from researchers.



MICROVENTURES



For Researchers

Researchers can utilize the DNA ID platform to connect with participants, collect applicable sequenced DNA, and utilize already analyzed data and insights on the platform. Researchers can choose between a Basic, Standard, or Advanced subscription. Subscriptions include:


1. *Basic*: includes user authentication, web survey collection, unlimited questions, and unlimited responses.
2. *Standard*: includes all basic functionality and genomic connection, data collection via web, iOS, or Android, and automated data analysis.
3. *Advanced*: includes all standard functionality and health records connection, data export and sharing, and marketplace access.

DNA ID solutions help clients organize their patients in a more research-friendly way, enabled by technology. DNA ID combines its capabilities in business strategy, technology strategy, and operations/functional strategy to help advocacy groups and researchers shape and execute their research objectives. The patient registry solution includes:



Data Collection

Enabling data collection to revolve around putting the patient first. The company uses passive data



Data Analysis

Enabling custom analytic reports based on data collection. Easy to work with APIs and programming



Data Sharing

The company enables patients to be a part of global research network. Creating a double-opt-in




MICROVENTURES

collection enabling longitudinal studies over time.

interfaces to enable quicker analysis of good, clean data.

marketplace for patients to unlock their records.

Use of Proceeds and Product Roadmap



DNA ID plans to use the majority of proceeds from this raise on future wages, general marketing, and general working capital. If the minimum amount of \$25,000 is raised, the company plans to spend \$15,000 on future wages in order to hire a software engineer and a marketing/business development employee. The company will allocate \$4,500 to general working capital, \$3,000 for general marketing, and \$2,500 to cover marketing and other fees for this raise.

If the maximum amount of \$107,000 is raised, DNA ID plans to allocate \$74,500 to future wages in order to hire three software engineers and two marketing/business development employees. The company plans to use the remaining proceeds from this raise on the following:

- Research and development: \$10,000
- Expenses related to this campaign: \$2,500
- General marketing: \$10,000
- General working capital: \$10,000

Product Roadmap

The company has three main goals in the product development process:

1. Increase distribution of the platform by supporting Android devices.
2. Extend existing data storage infrastructure to be extensible through API development.
3. Increase the data inputs collected from the users including electronic health records.

The company intends to achieve these goals by spending on marketing, hiring additional staff to build out the platform, and developing new partnerships.

Business Model



MICROVENTURES


Initially, the company released its product as software-as-a-service for patient advocate groups. The product is free to use for contributors, and researchers can choose between three subscriptions: Basic for \$29 per month, Standard for \$129 per month, or Advanced for \$249 per month.

Additionally, the company plans to release a clinical trial recruitment platform in the future. The company will charge a transaction fee for organizations to connect with patients.

USER TRACTION

So far in 2019, the company has conducted a pilot program for data analysis and also partnered with Cure Rare Diseases to set up a patient registry and Your DNA to connect rare disease patients to genetic researchers in a safe, secure, and more efficient way.

The company released its app in the Apple store in August 2019 and acquired over 50 new users to reach a total of 320 total users. The company plans to allocate a portion of the proceeds from this raise towards general marketing to expand awareness of the platform. The company also plans to hire sales and business development employees to gain more partnerships.





HISTORICAL FINANCIALS

DNA ID began generating revenue in June 2019. The company has had two paid customers totaling just under \$1,000 in revenue.


DNA ID was incorporated in September 2018. In 2018, the company incurred roughly \$1,500 in expenses. Since inception as of August 2019, the company has incurred ~\$10,800 in total expenses. In 2019 through August, the company accrued total expenses of roughly \$36,000. The largest expense was for third-party contractors totaling \$16,800. Other significant expenses in 2019 have gone towards rent (\$2,072), meals and entertainment (\$2,100), and advertising (\$1,824).



MICROVENTURES



DNA ID has generated a year-to-date net loss of \$8,247 as of August. In the last four months of 2018, the company generated a net loss of roughly \$1,700. The company currently has over \$26,000 in cash on hand with an estimated runway of more than one year.



INDUSTRY AND MARKET ANALYSIS

Due to the small market of each rare disease, funding is scarce for researchers, and there is typically a lack of existing literature and research.ⁱⁱ Although there is a small market for each rare disease individually, combined, rare diseases affect around 400 million people globally, more than the U.S. population. There are also currently roughly 7,000 distinct types of rare and genetic diseases, and 50% of these rare diseases don't have a foundation or research support group. On average, it takes eight years for rare disease patients to receive an accurate diagnosis, and 95% of rare diseases don't even have an FDA approved treatment.ⁱⁱⁱ Studies have found that DNA sequencing can help detect rare diseases quickly and contribute to research to find cures. By accelerating the diagnosis, treatment options may become available sooner and at an earlier stage.^{iv}

The global genetic testing market was valued at an estimated \$7.5 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 11.3% through 2025 to reach \$17.6 billion.^v There are thousands of genetics tests available that can be used in the following ways:^{vi}

- **Diagnostics:** Identifies whether an individual has a certain genetic disease (e.g. cystic fibrosis and Huntington's disease)
- **Predictive genetic testing:** Determines whether an individual may have an increased risk for a specific disease
- **Screening genetic tests:** Tests performed on a large segment of the asymptomatic population to determine whether they need more definitive testing to diagnose a genetic disease (e.g. newborn screening and noninvasive prenatal screening)
- **Pharmacogenomics:** Identifies variations in an individual's genetic makeup to determine whether a drug is suitable for that patient
- **Whole-genome and whole-exome sequencing:** Most often used in complex diagnostic cases, but is being explored for use in asymptomatic individuals to predict future disease
- **Tumor analysis:** Examines genetic markers in a tumor to determine which genetic alterations are driving tumor growth and which therapies would be most effective



MICROVENTURES

While most genetic tests are only available through a healthcare provider, the direct-to-consumer (DTC) genetic testing market still covers a wide range of tests, including genetic diseases, traits (e.g. male hair loss), wellness, carrier status, and paternity testing.^{vii} Prices of DTC genetic tests range from less than \$100 to a few thousand dollars.^{viii} Consumers are encouraged to speak with a doctor or healthcare practitioner about these tests before making health-related decisions.^{ix} According to biotechnology research firm Kalorama Information, the global DTC genetic health testing market was valued at \$99 million in 2017 and is estimated to grow at an average rate of 25.6% to reach \$310 million in 2022.^x

COMPETITORS

RDMD: Founded in 2017, RDMD is a medical data science company with a mission of empowering patients and communities to accelerate the development of treatments for rare diseases of all kinds. The company helps to identify patients and generate regulatory-grade evidence to enable drug approvals and real-world evidence in rare diseases. Through its technology platform, patients and families can benefit from their own data while researchers gain deep insights to accelerate rare disease research and drug development. In August 2018, RDMD raised \$3 million led by Lux Capital with participation from Village Global, First Round's Healthcare Co-Op, Garuda, Shasta Ventures, and various angel investors.^{xi}

Backpack Health: Founded in 2016, Backpack Health's goal is to make it easy for everyone to access, own, and control their health information to support better health care and attain better health for themselves, their loved ones, and their communities. The company provides a platform for organizations to engage patients, collect up-to-date data, and build communities around the globe. The Backpack Health platform provides users with an Emergency Share Card to detail their most crucial health information and allows users to create a unique, secure web address to provide loved ones and health professionals in case of an emergency. In March 2019, the company partnered with StickyJ to improve its medical ID accessories by engraving a simple URL on it.^{xii}

LunaDNA: A subsidiary of LunaPBC, LunaDNA is a community-owned, health and DNA platform dedicated to advancing research through community engagement. In December 2018, LunaDNA received precedent-setting qualification from the SEC to recognize an individual's genomic and health data as currency with which to acquire ownership of a company. This allows members of LunaDNA to securely provide their health data, help advance research, and receive shares in the company as compensation. In May 2018, LunaPBC raised \$4.6 million in funding from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illuma Ventures, and Osage University Partners. The company has raised a total of \$7.6 million.^{xiii}

Nebula Genomics: Founded in 2016, Nebula Genomics leverages blockchain technology to empower people to monetize their own personal genomic data. Consumers can purchase a Whole Genome Sequencing kit and the company will send the customer a saliva collection kit. Once the customer sends it back, the company will extract, sequence, and analyze the DNA in order to provide details on ancestry, inherited traits, and microbiome composition. Customers can also purchase a subscription to Nebula Explore, a stream of curated content that gives customers insight into the latest genomic research and also allows customers to participate in scientific discovery and potentially earn money from participation. The Nebula Sequencing kit costs \$149.99 while the Nebula Explore costs \$6.99 per month.^{xiv} In August 2018, the company raised \$4.3 million in funding from Khosla Ventures, Arch Venture Partners, Fenbushi Capital, F-Prime Capital Partners, and more.^{xv}

Invitae (NYSE: NVT): Invitae Corporation provides genetic information services including processing DNA-containing samples, analyzing information related to patient-specific genetic variation, and generating test



MICROVENTURES

reports for clinicians and patients. The company provides a number of tests including genes associated with neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and more. Invitae is also the parent company of AltaVoice, a platform that collects, curates, and delivers data from patients to clinicians, and CancerGene Connect, a platform that collects and manages genetic family histories to deliver personalized genetic risk information. In 2018, the company generated revenue of \$147.7 million, up from \$68.2 million in 2017.^{xvi}

EXECUTIVE TEAM



Craig Calderone, Founder and CEO: Prior to founding DNA ID, Craig held senior sales engineering roles at Leanplum, a fully integrated optimization solution for mobile apps, and at Chartbeat, a company that gives publishers the insights to better engage audiences. Previously, Craig was a Program Manager at Techstars where he advised various startups and helped them prepare for their future financing rounds. Craig graduated with a B.A. in Economics from Villanova University.

INVESTMENT TERMS

Security Type: Crowd Note

Round Size: Min: \$25,000 Max: \$107,000

Valuation Cap: \$3 million or \$4 million

Conversion Provisions: In connection with an equity financing of at least \$1 million, the Company has the option to convert the Crowd Note into shares of non-voting preferred stock (Conversion Shares) at a price based on the lower of (A) the price paid per share for Preferred Stock by investors in the Qualified Equity Financing or (B) the price paid per share paid on a \$3 million or \$4 million valuation cap. Please refer to the Crowd Note for a complete description of the terms of the Crowd Note, including the conversion provisions.

Transaction Type: Primary

PAST FINANCING

Since inception, the company has raised \$40,000 from friends and family in the form of SAFE Notes. In August 2019, the company was accepted into the Antler Accelerator Program. The program provides DNA ID with mentorship, investors, advisors and potentially a \$150,000 investment in the form of a convertible note.

PRESS

Clinical OMICS: [YourDNA, DNA ID Partner to Connect Rare Disease Patients and Researchers](#)

WBOC: [YourDNA and DNA ID Announce Partnership to Further Improve Genetic Research](#)

RISKS

The information provided herein is not intended to be, nor should it be construed or used as, investment, tax or legal advice, a recommendation to purchase, or an offer to sell securities of the company. You should rely on the offering statement and documents attached as exhibits to the offering statement when making any investment decision. An investment in the company is not suitable for all investors.



MICROVENTURES

Investment Risk

An investment in the company is speculative, and as such is not suitable for anyone without a high tolerance for risk and a low need for liquidity. You should invest only if you are able to bear the risk of losing your entire investment. There can be no assurance that that investors will receive any return of capital or profit. Investors should have the financial ability and willingness to accept the risks (including, among other things, the risk of loss of their entire investment and the risks of lack of liquidity) that are characteristic of private placement investments. There will be no public market for the securities being offered, applicable securities laws will restrict any transfer of the securities, and the securities will not be transferable without the company's consent.

Company Risk

The company's industry is highly competitive, and the company may not be able to compete effectively against the other businesses in its industry. The company is subject to a number of significant risks that could result in a reduction in its value and the value of the company securities, potentially including, but not limited to:

- Rapidly changing consumer preferences and market trends,
- Inability to expand and maintain market acceptance for the company's services and products,
- Inability to gain access to international markets and comply with all applicable local laws and regulations,
- Inability to achieve management's projections for growth, to maintain or increase historical rates of growth, to achieve growth based on past or current trends, or to effectively manage rapid growth,
- Inability to develop, maintain and expand successful marketing relationships, affiliations, joint ventures and partnerships that may be needed to continue and accelerate the company's growth and market penetration,
- Inability to keep pace with rapid industry, technological and market changes that could affect the company's services, products and business,
- Technological problems, including potentially widespread outages and disruptions in Internet and mobile commerce,
- Potential costs and business disruption that may result if the company's customers complain or assert claims regarding the company's technology,
- Failure to adequately address data security and privacy concerns in compliance with U.S. and international laws, rules and policies,
- Performance issues arising from infrastructure changes, human or software errors, website or third-party hosting disruptions, network disruptions or capacity constraints due to a number of potential causes including technical failures, cyber-attacks, security vulnerabilities, natural disasters or fraud,
- Inability to adequately secure and protect intellectual property rights,
- Potential claims and litigation against the company for infringement of intellectual property rights and other alleged violations of law,
- Difficulties in complying with applicable laws and regulations, and potential costs and business disruption if the company becomes subject to claims and litigation for legal non-compliance,
- Changes in laws and regulations materially affecting the company's business,
- Liability risks and labor costs and requirements that may jeopardize the company's business,
- Dependence on and inability to hire or retain key members of management and a qualified workforce,
- Ongoing need for substantial additional capital to support operations, to finance expansion and/or to maintain competitive position,
- Issuance of additional company equity securities at prices dilutive to existing equity holders,



MICROVENTURES

- Potential significant and unexpected declines in the value of company equity securities, including prior to, during, and after an initial public offering, and
- Inability of the company to complete an initial public offering of its securities, merger, buyout or other liquidity event.

ⁱ <https://www.the-scientist.com/careers/the-challenges-of-rare-disease-research-32928>

ⁱⁱ <https://www.the-scientist.com/careers/the-challenges-of-rare-disease-research-32928>

ⁱⁱⁱ <https://globalgenes.org/rare-facts/>

^{iv} <https://informeddna.com/opening-a-world-of-hope-for-patients-and-families-living-with-rare-diseases/>

^v <https://www.prnewswire.com/news-releases/the-global-genetic-testing-market-was-valued-at-7-501-90-million-in-2017-and-is-projected-to-reach-17-606-70-million-by-2025--growing-at-a-cagr-of-11-3-from-2018-to-2025--300923117.html>

^{vi} <https://www.ama-assn.org/content/genetic-testing>

^{vii} <http://aboutgeneticcounselors.com/Genetic-Testing/What-is-At-Home-Genetic-Testing>

^{viii} <https://www.consumer.ftc.gov/articles/0166-direct-consumer-genetic-tests>

^{ix} Ibid.

^x <https://www.prnewswire.com/news-releases/direct-to-consumer-genetic-health-testing-market-to-reach-310-million-says-report-300581607.html>

^{xi} <https://www.businesswire.com/news/home/20180820005057/en/RDMD-Secures-3-Million-Seed-Funding-Drive>

^{xii} <https://hitconsultant.net/2019/03/05/backpack-health-sticky-j-partnership/#.XH-gogzY2>

^{xiii} <https://www.prnewswire.com/news-releases/lunapbc-raises-4-6-million-to-accelerate-company-growth-and-drive-health-breakthroughs-300846139.html>

^{xiv} <https://portal.nebula.org/get-sequenced>

^{xv} <https://www.businesswire.com/news/home/20180829005484/en/Nebula-Genomics-Raises-4.3M-Seed-Financing-Leading>

^{xvi} <https://finance.yahoo.com/quote/NVTA/financials?p=NVTA>

EXHIBIT C
Subscription Agreement

Subscription Agreement

THE SECURITIES ARE BEING OFFERED PURSUANT TO SECTION 4(A)(6) OF THE SECURITIES ACT OF 1933 (THE "SECURITIES ACT") AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN. THE PURCHASE OF THE SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE LOSS OF THEIR ENTIRE INVESTMENT.

dna ID, Inc.
29 Little West 12th St.
New York, NY 10014

Ladies and Gentlemen:

The undersigned understands that dna ID, Inc., a Corporation organized under the laws of Delaware (the "Company"), is offering up to \$107,000 in Crowd Notes (the "Securities") in a Regulation CF Offering. This Offering is made pursuant to the Form C/A, dated November 21, 2019 (the "Form C/A"). The undersigned further understands that the Offering is being made pursuant to Section 4(a)(6) of the Securities Act and Regulation CF under the JOBS Act of 2012 and without registration of the Securities under the Securities Act of 1933, as amended (the "Securities Act").

1. Subscription. Subject to the terms and conditions hereof and the provisions of the Form C/A, the undersigned hereby irrevocably subscribes for the Securities set forth on the signature page hereto for the aggregate purchase price set forth on the signature page hereto, which is payable as described in Section 4 hereof. The undersigned acknowledges that the Securities will be subject to restrictions on transfer as set forth in this subscription agreement (the "Subscription Agreement").

2. Acceptance of Subscription and Issuance of Securities. It is understood and agreed that the Company shall have the sole right, at its complete discretion, to accept or reject this subscription, in whole or in part, for any reason and that the same shall be deemed to be accepted by the Company only when it is signed by a duly authorized officer of the Company and delivered to the undersigned at the Closing referred to in Section 3 hereof. Subscriptions need not be accepted in the order received, and the Securities may be allocated among subscribers.

3. The Closing. The closing of the purchase and sale of the Securities (the "Closing") shall take place at 11:59 p.m. Pacific standard time on December 9, 2019, or at such other time and place as the Company may designate by notice to the undersigned.

4. Payment for Securities. Payment for the Securities shall be received by Evolve Bank & Trust Co. (the "Escrow Agent") from the undersigned of immediately available funds or other means approved by the Company at least two days prior to the Closing, in the amount as set forth on the signature page hereto. Upon the Closing, the Escrow Agent shall release such funds to the Company. The undersigned shall receive notice and evidence of the entry of the number of the Securities owned by undersigned reflected on the books and records of the Company, which shall bear a notation that the Securities were sold in reliance upon an exemption from registration under the Securities Act.

5. Representations and Warranties of the Company. As of the Closing, the Company represents and warrants that:

- a) The Company is duly formed and validly existing under the laws of Delaware, with full power and authority to conduct its business as it is currently being conducted and to own its assets; and has secured any other authorizations, approvals, permits and orders required by law for the conduct by the Company of its business as it is currently being conducted.

- b) The Securities have been duly authorized and, when issued, delivered and paid for in the manner set forth in this Subscription Agreement, will be validly issued, fully paid and nonassessable, and will conform in all material respects to the description thereof set forth in the Form C/A.
- c) The execution and delivery by the Company of this Subscription Agreement and the consummation of the transactions contemplated hereby (including the issuance, sale and delivery of the Securities) are within the Company's powers and have been duly authorized by all necessary corporate action on the part of the Company. Upon full execution hereof, this Subscription Agreement shall constitute a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies and (iii) with respect to provisions relating to indemnification and contribution, as limited by considerations of public policy and by federal or securities, "blue sky" or other similar laws of such jurisdiction (collectively referred to as the "State Securities Laws").
- d) Assuming the accuracy of the undersigned's representations and warranties set forth in Section 6 hereof, no order, license, consent, authorization or approval of, or exemption by, or action by or in respect of, or notice to, or filing or registration with, any governmental body, agency or official is required by or with respect to the Company in connection with the execution, delivery and performance by the Company of this Subscription Agreement except (i) for such filings as may be required under Regulation CF promulgated under the Securities Act, or under any applicable State Securities Laws, (ii) for such other filings and approvals as have been made or obtained, or (iii) where the failure to obtain any such order, license, consent, authorization, approval or exemption or give any such notice or make any filing or registration would not have a material adverse effect on the ability of the Company to perform its obligations hereunder.

6. Representations and Warranties of the Undersigned. The undersigned hereby represents and warrants to and covenants with the Company that:

a) General.

- i. The undersigned has all requisite authority (and in the case of an individual, the capacity) to purchase the Securities, enter into this Subscription Agreement and to perform all the obligations required to be performed by the undersigned hereunder, and such purchase will not contravene any law, rule or regulation binding on the undersigned or any investment guideline or restriction applicable to the undersigned.
- ii. The undersigned is a resident of the state set forth on the signature page hereto and is not acquiring the Securities as a nominee or agent or otherwise for any other person.
- iii. The undersigned will comply with all applicable laws and regulations in effect in any jurisdiction in which the undersigned purchases or sells Securities and obtain any consent, approval or permission required for such purchases or sales under the laws and regulations of any jurisdiction to which the undersigned is subject or in which the undersigned makes such purchases or sales, and the Company shall have no responsibility therefor.
- iv. Including the amount set forth on the signature page hereto, in the past twelve (12) month period, the undersigned has not exceeded the investment limit as set forth in Rule 100(a)(2) of Regulation CF.

b) Information Concerning the Company.

- i. The undersigned has received a copy of the Form C/A. With respect to information provided by the Company, the undersigned has relied solely on the information contained in the Form C/A to make the decision to purchase the Securities.
- ii. The undersigned understands and accepts that the purchase of the Securities involves various risks, including the risks outlined in the Form C/A and in this Subscription Agreement. The undersigned represents that it is able to bear any and all loss associated with an investment in the Securities.

iii. The undersigned confirms that it is not relying and will not rely on any communication (written or oral) of the Company, MicroVenture Marketplace Inc., or any of their respective affiliates, as investment advice or as a recommendation to purchase the Securities. It is understood that information and explanations related to the terms and conditions of the Securities provided in the Form C/A or otherwise by the Company, MicroVenture Marketplace Inc. or any of their respective affiliates shall not be considered investment advice or a recommendation to purchase the Securities, and that neither the Company, MicroVenture Marketplace Inc. nor any of their respective affiliates is acting or has acted as an advisor to the undersigned in deciding to invest in the Securities. The undersigned acknowledges that neither the Company, MicroVenture Marketplace Inc. nor any of their respective affiliates have made any representation regarding the proper characterization of the Securities for purposes of determining the undersigned's authority or suitability to invest in the Securities.

iv. The undersigned is familiar with the business and financial condition and operations of the Company, all as generally described in the Form C/A. The undersigned has had access to such information concerning the Company and the Securities as it deems necessary to enable it to make an informed investment decision concerning the purchase of the Securities.

v. The undersigned understands that, unless the undersigned notifies the Company in writing to the contrary at or before the Closing, each of the undersigned's representations and warranties contained in this Subscription Agreement will be deemed to have been reaffirmed and confirmed as of the Closing, taking into account all information received by the undersigned.

vi. The undersigned acknowledges that the Company has the right in its sole and absolute discretion to abandon this Offering at any time prior to the completion of the Offering. This Subscription Agreement shall thereafter have no force or effect and the Company shall return any previously paid subscription price of the Securities, without interest thereon, to the undersigned.

vii. The undersigned understands that no federal or state agency has passed upon the merits or risks of an investment in the Securities or made any finding or determination concerning the fairness or advisability of this investment.

c) No Guaranty.

The undersigned confirms that the Company has not (A) given any guarantee or representation as to the potential success, return, effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities or (B) made any representation to the undersigned regarding the legality of an investment in the Securities under applicable legal investment or similar laws or regulations. In deciding to purchase the Securities, the undersigned is not relying on the advice or recommendations of the Company and the undersigned has made its own independent decision that the investment in the Securities is suitable and appropriate for the undersigned.

d) Status of Undersigned.

The undersigned has such knowledge, skill and experience in business, financial and investment matters that the undersigned is capable of evaluating the merits and risks of an investment in the Securities. With the assistance of the undersigned's own professional advisors, to the extent that the undersigned has deemed appropriate, the undersigned has made its own legal, tax, accounting and financial evaluation of the merits and risks of an investment in the Securities and the consequences of this Subscription Agreement. The undersigned has considered the suitability of the Securities as an investment in light of its own circumstances and financial condition and the undersigned is able to bear the risks associated with an investment in the Securities and its authority to invest in the Securities.

e) Restrictions on Transfer or Sale of Securities.

i. The undersigned is acquiring the Securities solely for the undersigned's own beneficial account, for investment purposes, and not with a view to, or for resale in connection with, any distribution of the Securities. The undersigned understands that the Securities have not been registered under the Securities Act or any State Securities Laws by reason of specific exemptions under the provisions thereof which depend in part upon the investment intent of the undersigned and of the other representations made by the undersigned in this Subscription Agreement. The undersigned understands that the Company is relying

upon the representations and agreements contained in this Subscription Agreement (and any supplemental information) for the purpose of determining whether this transaction meets the requirements for such exemptions.

ii. The undersigned understands that the Securities are restricted from transfer for a period of time under applicable federal securities laws and that the Securities Act and the rules of the U.S. Securities and Exchange Commission (the "Commission") provide in substance that the undersigned may dispose of the Securities only pursuant to an effective registration statement under the Securities Act, an exemption therefrom or as further described in Rule 501 of Regulation CF, after which certain state restrictions may apply. The undersigned understands that the Company has no obligation or intention to register any of the Securities, or to take action so as to permit sales pursuant to the Securities Act. Even when the Securities become freely transferrable, a secondary market in the Securities may not develop. Consequently, the undersigned understands that the undersigned must bear the economic risks of the investment in the Securities for an indefinite period of time.

iii. The undersigned agrees: (A) that the undersigned will not sell, assign, pledge, give, transfer or otherwise dispose of the Securities or any interest therein, or make any offer or attempt to do any of the foregoing, except pursuant to Rule 501 of Regulation CF.

7. Conditions to Obligations of the Undersigned and the Company. The obligations of the undersigned to purchase and pay for the Securities specified on the signature page hereto and of the Company to sell the Securities are subject to the satisfaction at or prior to the Closing of the following conditions precedent: the representations and warranties of the Company contained in Section 5 hereof and of the undersigned contained in Section 6 hereof shall be true and correct as of the Closing in all respects with the same effect as though such representations and warranties had been made as of the Closing.

8. Obligations Irrevocable. Following the Closing, the obligations of the undersigned shall be irrevocable.

9. Legend. The certificates, book entry or other form of notation representing the Securities sold pursuant to this Subscription Agreement will be notated with a legend or designation, which communicates in some manner that the Securities were issued pursuant to Section 4(a)(6) of the Securities Act and may only be resold pursuant to Rule 501 of Regulation CF.

10. Waiver, Amendment. Neither this Subscription Agreement nor any provisions hereof shall be modified, changed, discharged or terminated except by an instrument in writing, signed by the party against whom any waiver, change, discharge or termination is sought.

11. Assignability. Neither this Subscription Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by either the Company or the undersigned without the prior written consent of the other party.

12. Waiver of Jury Trial. THE UNDERSIGNED IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING ARISING OUT OF THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT.

13. Submission to Jurisdiction. With respect to any suit, action or proceeding relating to any offers, purchases or sales of the Securities by the undersigned ("Proceedings"), the undersigned irrevocably submits to the jurisdiction of the federal or state courts located in Delaware, which submission shall be exclusive unless none of such courts has lawful jurisdiction over such Proceedings.

14. Governing Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles thereof.

15. Section and Other Headings. The section and other headings contained in this Subscription Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Subscription Agreement.

16. Counterparts. This Subscription Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

17. Notices. All notices and other communications provided for herein shall be in writing and shall be deemed to have been duly given if delivered personally or sent by registered or certified mail, return receipt requested, postage prepaid or email to the following addresses (or such other address as either party shall have specified by notice in writing to the other):

If to the Company:	29 Little West 12 th St. New York, NY 10014 Attention: Craig Calderone
with a copy to:	BEVILACQUA PLLC 1050 Connecticut Avenue, NW Suite 500 Washington, DC 20036 Attention: Louis A. Bevilacqua, Esq.
If to the Purchaser:	[PURCHASER ADDRESS] [E-MAIL ADDRESS]

18. Binding Effect. The provisions of this Subscription Agreement shall be binding upon and accrue to the benefit of the parties hereto and their respective heirs, legal representatives, successors and assigns.

19. Survival. All representations, warranties and covenants contained in this Subscription Agreement shall survive (i) the acceptance of the subscription by the Company, (ii) changes in the transactions, documents and instruments described in the Form C/A which are not material or which are to the benefit of the undersigned and (iii) the death or disability of the undersigned.

20. Notification of Changes. The undersigned hereby covenants and agrees to notify the Company upon the occurrence of any event prior to the closing of the purchase of the Securities pursuant to this Subscription Agreement, which would cause any representation, warranty, or covenant of the undersigned contained in this Subscription Agreement to be false or incorrect.

21. Severability. If any term or provision of this Subscription Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Subscription Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.

SIGNATURE PAGE FOLLOWS

IN WITNESS WHEREOF, the undersigned has executed this Subscription Agreement this [DAY] OF [MONTH], [YEAR].

PURCHASER (if an individual):
By _____ Name:

PURCHASER (if an entity):
_____ Legal Name of Entity
By _____ Name: Title:

State/Country of Domicile or Formation: _____

The offer to purchase Securities as set forth above is confirmed and accepted by the Company as to [amount of Securities to be acquired by Purchaser] for [total amount to be paid by Purchaser].

dna ID, Inc.
By _____ Name: Title:

EXHIBIT D
Crowd Note

THIS INSTRUMENT AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE ACT. FOR ONE YEAR FROM THE DATE OF THIS INSTRUMENT, SECURITIES SOLD IN RELIANCE ON REGULATION CROWDFUNDING UNDER THE ACT MAY ONLY BE TRANSFERRED TO THE COMPANY, TO AN "ACCREDITED INVESTOR" WITHIN THE MEANING OF RULE 501 OF REGULATION D UNDER THE ACT, AS PART OF AN OFFERING REGISTERED UNDER THE SECURITIES ACT WITH THE SEC, OR TO A MEMBER OF INVESTOR'S FAMILY OR THE EQUIVALENT, TO A TRUST CONTROLLED BY THE INVESTOR, TO A TRUST CREATED FOR THE BENEFIT OF A MEMBER OF THE FAMILY OF THE INVESTOR OR EQUIVALENT, OR IN CONNECTION WITH THE DEATH OR DIVORCE OF THE INVESTOR OR OTHER SIMILAR CIRCUMSTANCE. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO INVESTOR IN CONNECTION WITH THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

dna ID, Inc.

CROWD NOTE

FOR VALUE RECEIVED, dna ID, Inc. (the "**Company**"), hereby promises to pay to each investor (the "**Investor**") who is recorded in MicroVenture Marketplace Inc., (the "**Platform**") records as having subscribed to this security (the "**Crowd Note**") the principal sum of his/her subscription (the "**Purchase Price**") unless converted into equity securities pursuant to Section 2.

The "**Valuation Cap**" is \$3 or \$4 million.

The "**Offering End Date**" is December 9, 2019.

1. Definitions.

- a. "**Conversion Shares**" shall mean with respect to a conversion pursuant to Section 2, shares of the Company's Preferred Stock issued in the Qualified Equity Financing.
- b. "**Conversion Price**" with respect to a conversion pursuant to Section 2 shall equal:
 - i. Investors that purchase the first Fifty-Three Thousand, Five Hundred (53,500) Crowd Notes and thereby fund the first Fifty-Three Thousand, Five Hundred Dollars (\$53,500) will receive Crowd Notes with a conversion provision based on a \$3,000,000 (\$3 million) valuation cap instead of a \$4,000,000 (\$6 million) valuation cap. That means, in connection with equity financing of at least \$1,000,000, the company has the option to convert the Crowd Note into non-voting preferred shares (Conversion Shares) at a price based on the lower of (A) the price per unit paid for Preferred Shares by investors in the Qualified Equity Financing or (B) the price per share based on a \$3,000,000 (\$3 million) valuation cap (instead of \$4 million); or
 - ii. The lower of (A) the price paid per share for Preferred Stock by the investors in the Qualified Equity Financing or (B) the quotient resulting from dividing (1) the \$4,000,000 (\$4 million) Valuation Cap by (2) the Fully-Diluted Capitalization immediately prior to the closing of the Qualified Equity Financing.
- c. "**Corporate Transaction**" shall mean:

- i. the closing of the sale, transfer or other disposition of all or substantially all of the Company's assets,
 - ii. the consummation of the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold at least 50% of the voting power of the capital stock of the Company or the surviving or acquiring entity), the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of the Company's securities), of the Company's securities if, after such closing, such person or group of affiliated persons would hold 50% or more of the outstanding voting stock of the Company (or the surviving or acquiring entity), or
 - iii. the IPO, liquidation, dissolution or winding up of the Company; provided, however, that a transaction shall not constitute a Corporate Transaction if its sole purpose is to change the state of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately prior to such transaction.
- d. **"Corporate Transaction Payment"** shall mean an amount equal to two times (2X) the Purchase Price. If there are not enough funds to pay the Investors in full, then proceeds from the respective transaction will be distributed with equal priority and pro rata among Investors in proportion to their Purchase Price.
- e. **"Date of Issuance"** shall mean the date upon which the Investor subscription is recorded in the Platform's records as having been accepted by the Company at the date of closing.
- f. **"Fully-Diluted Capitalization"** shall mean the number of shares of outstanding Common Stock of the Company on a fully-diluted basis, including (i) conversion or exercise of all securities convertible into or exercisable for Common Stock, (ii) exercise of all outstanding options and warrants to purchase Common Stock and, in the case of Section 1(b), (iii) the shares reserved or authorized for issuance under the Company's existing stock option plan or any stock option plan created or increased in connection with such transaction; but excluding, for this purpose, the conversion contemplated by the applicable provision of Section 2.
- g. **"Irrevocable Proxy"** shall mean the agreement appointing the Platform or an affiliate of the Platform as the sole and exclusive attorney and proxy of the Investor, with full power of substitution and re-substitution, to vote and exercise all voting and related rights with respect to all of the securities of the Company that now are or hereafter may be beneficially owned by Investor.
- h. **"Major Investor"** shall mean any Investor in a Crowd Note in which the Purchase Price is equal to or greater than \$25,000.
- i. **"Maximum Raise Amount"** shall mean \$107,000 under Regulation CF.
- j. **"Outstanding Principal"** shall mean the total of the Purchase Price
- k. **"Qualified Equity Financing"** shall mean the first sale (or series of related sales) by the Company of its Preferred Stock following the Date of Issuance from which the Company receives gross proceeds of not less than \$1,000,000 (excluding the aggregate amount of

securities converted into Preferred Stock in connection with such sale or series of related sales).

1. **“Shadow Series”** shall mean shares of a series of the Company’s Preferred Stock that is identical in all respects to the shares of Preferred Stock issued in the Qualified Equity Financing (e.g., if the Company sells Series A Preferred Stock in the Qualified Equity Financing, the Shadow Series would be Series A-1 Preferred Stock), except that the liquidation preference per share of the Shadow Series shall equal the Conversion Price (as determined pursuant to Section 2) and the following additional differences:
 - i. Shadow Series shareholders shall grant their vote on any matter that is submitted to a vote or for the consent of the stockholders of the Company (except for on matters required by law) by Irrevocable Proxy;
 - ii. Shadow Series shareholders shall receive quarterly business updates from the company through the Platform but will have no additional information or inspection rights (except with respect to such rights which are required by law).
- m. **“Target CF Minimum”** shall mean \$25,000 raised via Regulation CF.

2. Conversion of the Crowd Note.

1. **Qualified Equity Financing.** Upon the occurrence of a Qualified Equity Financing the Crowd Note will convert into Conversion Shares pursuant to the following:
 - a. If the Investor is not a Major Investor, the Crowd Note will convert into Conversion Shares upon the earlier of (i) the Company’s election or (ii) a Corporate Transaction.
 - b. If the Investor is a Major Investor, the Company will convert the Crowd Note into Conversion Shares prior to the closing of the Qualified Equity Financing.
2. **Conversion Mechanics.** Company shall convert the Crowd Note into Conversion Shares equal to the quotient obtained by dividing the Outstanding Principal by the Conversion Price.
 - a. The issuance of Conversion Shares pursuant to the conversion of this Crowd Note shall be upon and subject to the same terms and conditions applicable to the stock sold in the Qualified Equity Financing; provided, however, that if the Investor is not a Major Investor, the Investor shall receive shares of a Shadow Series with certain limited rights.
3. **Corporate Transaction.** In the event of a Corporate Transaction, the Company shall notify the Investor in writing of the terms of the Corporate Transaction.
 - a. If the Corporate Transaction occurs prior to a Qualified Equity Financing, the Investor shall receive the higher value received by either:
 - i. Converting this Crowd Note into that number of Conversion Shares equal to the quotient obtained by dividing the Purchase Price by the Conversion Price, or
 - ii. Obtaining the Corporate Transaction Payment.
 - b. If the Corporate Transaction occurs after a Qualified Equity Financing the Company shall convert this Crowd Note into Conversion Shares pursuant to Section 2 (a).
4. **Mechanics of Conversion.** As promptly as practicable after the conversion of this Crowd Note, the Company at its expense will issue and deliver to the Investor, upon surrender of this Crowd

Note, the respective number of Conversion Shares.

5. **Note Completion.** This Crowd Note will terminate upon the earlier of: (a) a conversion of the entire Purchase Price under this Crowd Note into Conversion Shares; or (b) the payment of amounts due to the Investor pursuant to Section 3 (a).

3. Representations and Warranties of the Company. In connection with the transactions provided for herein, the Company hereby represents and warrants to the Investor that:

1. **Organization, Good Standing and Qualification.** The Company is a corporation duly organized, validly existing, and in good standing and has all requisite corporate power and authority to carry on its business as now conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business or properties.
2. **Authorization.** Except for the authorization and issuance of the Conversion Shares issuable in connection with a Qualified Equity Financing or a Corporate Transaction, all corporate action has been taken on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Crowd Note. The Company has taken all corporate action required to make all of the obligations of the Company reflected in the provisions of this Crowd Note the valid and enforceable obligations they purport to be, and this Crowd Note, when executed and delivered by the Company, shall constitute the valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms.
3. **Offering.** Subject in part to the truth and accuracy of the Investor's representations set forth herein, the offer, sale and issuance of this Crowd Note are exempt from the registration requirements of any applicable state and federal securities laws, and neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption.
4. **Compliance with Other Instruments.** The execution, delivery and performance of this Crowd Note, and the consummation of the transactions contemplated hereby, will not constitute or result in a default, violation, conflict or breach in any material respect of any provision of the Company's current Certificate of Incorporation or bylaws, or in any material respect of any instrument, judgment, order, writ, decree, privacy policy or contract to which it is a party or by which it is bound, or, to its knowledge, of any provision of any federal or state statute, rule or regulation applicable to the Company.
5. **Valid Issuance of Stock.** The Conversion Shares, when issued, sold and delivered upon conversion of this Crowd Note, will be duly authorized and validly issued, fully paid and nonassessable, will be free of restrictions on transfer other than restrictions on transfer set forth herein and pursuant to applicable state and federal securities laws and, based in part upon the representations and warranties of the Investor herein, will be issued in compliance with all applicable federal and state securities laws.
6. **Intellectual Property.** To its knowledge, the Company owns or possesses or believes it can acquire on commercially reasonable terms sufficient legal rights to all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, trade secrets, licenses, domain names, mask works, information and proprietary rights and processes as are necessary to the conduct of its business as now conducted and as presently proposed to be conducted without any known conflict with, or infringement of, the rights of others. The Company has not received any communications alleging that the Company has violated or, by conducting its business, would violate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets, mask works or other

proprietary rights or processes of any other person.

7. **Litigation.** To the Company's knowledge, there is no private or governmental action, suit, proceeding, claim, arbitration or investigation pending before any agency, court or tribunal, foreign or domestic, or threatened against the Company or any of its properties or any of its officers or managers (in their capacities as such). There is no judgment, decree or order against the Company, or, to the knowledge of the Company, any of its directors or managers (in their capacities as such), that could prevent, enjoin, or materially alter or delay any of the transactions contemplated by this Crowd Note, or that could reasonably be expected to have a material adverse effect on the Company.

4. **Representations and Warranties of the Investor.** In connection with the transactions provided for herein, the Investor hereby represents and warrants to the Company that:

1. **Authorization.** This Crowd Note constitutes Investor's valid and legally binding obligation, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors' rights and (ii) laws relating to the availability of specific performance, injunctive relief or other equitable remedies.
2. **Purchase Entirely for Own Account.** Investor acknowledges that this Crowd Note is issued to Investor in reliance upon Investor's representation to the Company that the Crowd Note will be acquired for investment for Investor's own account.
3. **Required Information.** The Investor acknowledges they have received all the information necessary or appropriate for deciding whether to invest in this Crowd Note, and the Investor represents that the Investor has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of this instrument and the underlying securities and to obtain any additional information necessary to verify the accuracy of the information provided.
4. **Reliance on Advice.** The Investor acknowledges that they are not relying on the advice or recommendations of the Company or MicroVenture Marketplace Inc., or the affiliates of either, and the Investor has made its own independent decision that an investment in this instrument and the underlying securities is suitable and appropriate.
5. **Federal or State Agencies.** The Investor acknowledges that no federal or state agency has passed upon the merits or risks of an investment in this instrument and the underlying securities or made any finding or determination concerning the fairness or advisability of this investment.
6. **Voting and Inspection Rights.** The Investor acknowledges that if they are not a Major Investor they shall have limited voting, information and inspection rights.
7. **No Public Market.** The Investor acknowledges that no public market now exists for any of the securities issued by the Company, and that the Company has made no assurances that a public market will ever exist for this instrument and the securities to be acquired by the Investor hereunder.

5. **Miscellaneous.**

1. **Security.** This Crowd Note is a general unsecured obligation of the Company.

2. The Investor agrees to take any and all actions determined in good faith by the Company's board of directors to be advisable to reorganize this instrument and any shares of Capital Stock issued pursuant to the terms of this instrument into a special purpose vehicle or other entity designed to aggregate the interests of holders of Crowd Notes.
3. **Successors and Assigns.** The terms and conditions of this Crowd Note shall inure to the benefit of and be binding upon the respective successors and assigns of the parties hereto; provided, however, that the Company may not assign its obligations under this Crowd Note without the prior written consent of the Investor.
4. **Governing Law.** This Crowd Note shall be governed by and construed under the laws of Delaware as applied to other instruments made by Delaware residents to be performed entirely within the state of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of law.
5. **Notices.** All notices and other communications given or made pursuant to this Crowd Note shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient's next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt.
6. **Financing Agreements.** The Investor understands and agrees that the conversion of the Crowd Note into Conversion Shares may require the Investor's execution of certain agreements relating to the purchase and sale of such securities as well as registration, co sale, rights of first refusal, rights of first offer and voting rights, if any, relating to such securities. The Investor agrees to execute all such agreements in connection with the conversion so long as the issuance of Conversion Shares issued pursuant to the conversion of this Crowd Note are subject to the same terms and conditions applicable to the Preferred Stock sold in the Qualified Equity Financing (or the Shadow Series).
7. **Severability.** If one or more provisions of this Crowd Note are held to be unenforceable under applicable law, such provision shall be excluded from this Crowd Note and the balance of the Crowd Note shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.
8. **Transfer of a Crowd Note.** Subject to compliance with applicable federal and state securities laws (including the restrictions described in the legends to this Crowd Note), this Crowd Note and all rights hereunder are transferable in whole or in part by the Investor to any person or entity upon written notice to the Company.
9. **Escrow Procedures.** No investor funds shall be released from escrow until the Target CF Minimum is reached. The Target CF Minimum must be met on or before the Offering Date for funds to be released from escrow.
10. **Entire Agreement; Amendments and Waivers.** This Crowd Note constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof. The Company's agreements with each Investor are separate agreements, and the sales of the Crowd Notes to each Investor are separate sales.

6. **Dispute Resolution.**

1. **General Rule.** Any dispute under this Crowd Note will be resolved through arbitration, not through the court system. All arbitration will be conducted in Wilmington, Delaware unless both parties agree otherwise in writing in a specific case. All arbitration will be conducted before a single arbitrator in following the rules of the American Arbitration Association. Except as required by law, neither a party nor the arbitrator may disclose the existence, content or results of any arbitration without the prior written consent of the other parties.
 2. **Appeal of Award.** Within thirty days of a final award by the single arbitrator, either party may appeal the award for reconsideration by a three-arbitrator panel. If there is an appeal, the other party may cross-appeal within thirty days after notice of the appeal. The panel will reconsider all aspects of the initial award that are appealed, including related findings of fact.
 3. **Effect of Award.** Any award by the individual arbitrator that is not subject to appeal, and any panel award on appeal, shall be final and binding, except for any appeal right under the Federal Arbitration Act, and may be entered as a judgment in any court of competent jurisdiction.
 4. **No Class Action Claims.** NO ARBITRATION SHALL PROCEED ON A CLASS, REPRESENTATIVE, OR COLLECTIVE BASIS. No party may join, consolidate, or otherwise bring claims for or on behalf of two or more individuals or unrelated corporate entities in the same arbitration unless those persons are parties to a single transaction. An award in arbitration shall determine the rights and obligations of the named parties only, and only with respect to the claims in arbitration, and shall not (i) determine the rights, obligations, or interests of anyone other than a named party, or resolve any claim of anyone other than a named party, or (ii) make an award for the benefit of, or against, anyone other than a named party. No administrator or arbitrator shall have the power or authority to waive, modify, or fail to enforce this paragraph, and any attempt to do so, whether by rule, policy, and arbitration decision or otherwise, shall be invalid and unenforceable. Any challenge to the validity of this paragraph shall be determined exclusively by a court and not by the administrator or any arbitrator. If this paragraph shall be deemed unenforceable, then any proceeding in the nature of a class action shall be handled in court, not in arbitration.
7. **Approval.** The Company hereby represents that its Board of Directors, in the exercise of its fiduciary duty, has approved the Company's execution of this Crowd Note based upon a reasonable belief that the Purchase Price provided hereunder is appropriate for the Company after reasonable inquiry concerning the Company's financing objectives and financial situation. In addition, the Company hereby represents that it intends to use the proceeds primarily for the operations of its business, and not for any personal, family or household purpose.
8. **Subscription Procedure.** Each Investor, by providing his or her name, and subscription amount, confirms such investment through the Platform and has signed this Crowd Note electronically. Investor agrees that his or her electronic signature is the legal equivalent of his or her manual signature on this Crowd Note. By confirming, the Investor consents to be legally bound by the Crowd Note's terms and conditions, and to the terms and conditions of subscription established by the Platform. All Investors will be processed via Regulation CF. Investments may be accepted up to the Maximum Raise Amount up until the Offering End Date.

EXHIBIT E
Pitch Deck



DNA ID

A rare disease data marketplace working to accelerate cures together


Legal Notice

Any statements contained in this document regarding us, our expectations, beliefs, plans, objectives, assumptions, or future events or performance are not historical facts and are forward-looking statements. Investors are cautioned that these forward-looking statements involve uncertainties and risks that could cause actual performance and results of operations to differ materially from those anticipated. The forward-looking statements contained herein represent our judgment as of the date of publication of this document, and we caution you not to place undue reliance on such statements. We are a startup business and, as such, certain images contained in this document are for illustration purposes only. Our company, our management, and our affiliates assume no obligation to update any forward-looking statements to reflect events are the initial publication of this document or to reflect the occurrence of subsequent events.

Please see the end of this presentation for important risk disclosure information.

Problem

30% of rare
disease clinical
trials fail due to
patient recruitment



Rare Disease patients are hard to find, but they are out there

95%

of Rare Diseases
still do NOT have
an FDA approved
treatment

350M

People are affected
by a genetically
inherited Rare
Disease globally


7,000

Total Rare Diseases




Ref: Global Genes, Rare FACTS <https://globalgenes.org/rare-facts>

The world needs a Faster Solution



We build patient registry software for advocacy groups to collect genomic data, healthcare records, and patient-reported surveys to help accelerate research.

DNA ID is a solution




Unit Economics

~\$1,000
cost per patient
record recruited

~50
Patients
needed per
rare disease
trial

Rare Disease Targets



Ref: http://phrma-docs.phrma.org/files/cdfile/Rare-Disease-Update_FINAL.pdf (Accessed 4/25/19)

Client Case Study



- The Brain Recovery Project has a patient registry for families to register their children that have had brain surgery due to epilepsy. They have 194 respondents to a 400 question survey.
- Data collection was in progress through the RedCap software, and data analysis needed to be done. However, upon review of the data, we realized that it needed some clean up and further engagement.
- DNA ID created a data pipeline to integrate the survey response data into data analysis tools. Cleaning, formatting, and analyzing the response data

Contract Value	\$1,250
Acquisition	Private Facebook group of Rare Disease Registry Coordinators
Patient Volume	194 epilepsy patients
Function	Data analysis
Who we are working with	President & CEO
Duration	30-day Proof of Concept

We are the right team



Craig Calderone
Founder

LEANPLUM



Markus Gray
Software Engineer

Michael McDevitt
Software Engineer



Denise Sison
Bioinformatics
Data Scientist

Advisory board

Maggie Tyrpien

Abeona Therapeutics
Business Development



Viviana Volta, PhD
NYU Langone Medical
Center Research
Scientist

Anthony Albertorio
Consensys, data
marketplace



New Allocation & Milestones

2019-2020

Time	Q4 2019	Q1 2020	Q2 2020	Q3 2020
Focus	Hiring	Product Development	Sales & Marketing	Growth

Why we are raising

- ❖ Build software to streamline the data collection, data analysis, and marketplace transaction process
- ❖ Hire more engineers to redesign existing products
- ❖ Increase frequency of patient record transactions through additional advocacy partnerships
- ❖ Meet customer demand

Product Bundling Patient Registry Subscription

	Basic	Standard	Advanced
User Authentication	Included	Included	Included
Data Survey Collection	Desktop web	Web + iOS & Android mobile	Web + iOS & Android mobile
Genomic Connection	Not included	Included	Included
Health Records Connection	Not included	Not included	Included
Data Analysis	Not included	Included (Limited)	Included
Data Export & Sharing	Not included	Export to CSV	Marketplace access to global rare disease researcher network
Implementation	Included	Included	Included
Dedicated Customer Service	Not Included	Not Included	Included
Monthly Pricing	\$29/month	\$129/month	\$249/month

Benefits to Researchers

- Secure sensitive data storage and transfer using proprietary technology
- Additional data not otherwise able to collect
- Cleaned and formatted data pipeline for easy integration into data analysis tools
- Faster and more efficient patient recruiting process for targeted precision medicine

The DNA ID Advantage

Current Innovation & Technology

- Secure sensitive data storage and transfer
- Data aggregation of demographic data, patient-reported survey data, genomic data, Apple Health
- React Native iOS mobile application
- Full transparency on data usage using open science data model

Future Technology

- Anonymous comparison through electronic health record integration
- Android mobile application to mirror iOS user experience
- Points marketplace for redemption of healthcare services
- Notification system for data use requests

Risk Disclosures

Investment Risk

An investment in the company is speculative, and as such is not suitable for anyone without a high tolerance for risk and a low need for liquidity. You should invest only if you are able to bear the risk of losing your entire investment. There can be no assurance that investors will receive any return of capital or profit. Investors should have the financial ability and willingness to accept the risks (including, among other things, the risk of loss of their entire investment and the risks of lack of liquidity) that are characteristic of private placement investments. There will be no public market for the securities being offered, applicable securities laws will restrict any transfer of the securities, and the securities will not be transferable without the company's consent.

The information provided herein is not intended to be, nor should it be construed or used as, investment, tax or legal advice, a recommendation to purchase, or an offer to sell securities of the company. You should rely on the offering statement and documents attached as exhibits to the offering statement when making any investment decision. An investment in the company is not suitable for all investors.

Risk Disclosures

Company Risk

The company's industry is highly competitive, and the company may not be able to compete effectively against the other businesses in its industry. The company is subject to a number of significant risks that could result in a reduction in its value and the value of the company securities, potentially including, but not limited to:

- Rapidly changing consumer preferences and market trends,
- Inability to expand and maintain market acceptance for the company's services and products,
- Inability to gain access to international markets and comply with all applicable local laws and regulations,
- Inability to achieve management's projections for growth, to maintain or increase historical rates of growth, to achieve growth based on past or current trends, or to effectively manage rapid growth,
- Inability to develop, maintain and expand successful marketing relationships, affiliations, joint ventures and partnerships that may be needed to continue and accelerate the company's growth and market penetration,
- Inability to keep pace with rapid industry, technological and market changes that could affect the company's services, products and business,
- Technological problems, including potentially widespread outages and disruptions in Internet and mobile commerce,
- Potential costs and business disruption that may result if the company's customers complain or assert claims regarding the company's technology,
- Failure to adequately address data security and privacy concerns in compliance with U.S. and international laws, rules and policies,
- Performance issues arising from infrastructure changes, human or software errors, website or third-party hosting disruptions, network disruptions or capacity constraints due to a number of potential causes including technical failures, cyber-attacks, security vulnerabilities, natural disasters or fraud,

Risk Disclosures

Company Risk (cont'd)

- Inability to adequately secure and protect intellectual property rights,
- Potential claims and litigation against the company for infringement of intellectual property rights and other alleged violations of law,
- Difficulties in complying with applicable laws and regulations, and potential costs and business disruption if the company becomes subject to claims and litigation for legal non-compliance,
- Changes in laws and regulations materially affecting the company's business,
- Liability risks and labor costs and requirements that may jeopardize the company's business,
- Dependence on and inability to hire or retain key members of management and a qualified workforce,
- Ongoing need for substantial additional capital to support operations, to finance expansion and/or to maintain competitive position,
- Issuance of additional company equity securities at prices dilutive to existing equity holders,
- Potential significant and unexpected declines in the value of company equity securities, including prior to, during, and after an initial public offering, and
- Inability of the company to complete an initial public offering of its securities, merger, buyout or other liquidity event.

EXHIBIT F
Webinar Transcript



- Brett: Hi, everybody. This is Brett Andrews with MicroVentures. Thank you all for joining us for the webinar today. Today we'll be hearing from DNA ID, a community marketplace for genomic research. We are joined today by their founder and CEO, Craig Calderone. Prior to founding DNA ID, Craig held senior sales engineering roles at Leanplum, a fully integrated optimization solution for mobile apps, and at Chartbeat, a company that gives publishers the insights to better engage audiences. Previously, Craig was a program manager at Techstars where he advised various startups and helped them prepare for their future financing rounds. Craig graduated with a BA in Economics from Villanova University. How are you doing today, Craig?
- Craig: I'm doing well. Thanks for having me today.
- Brett: Yeah, likewise. Thanks for joining us. Real quick, before we get started, I want to just give everyone kind of the format for the day. Today, Craig's going to spend about 10 minutes or so, or somewhere around there, to get through the pitch deck. Hopefully you guys can see it on your screen at the moment. During that presentation, we encourage you to send in questions. If you go over to your Webinar Control Panel, there's a Questions tab. You can click there and feel free to submit during the presentation. They won't interrupt Craig. They're just going to go to me. Then when the presentation's over with, we will open up to Q&A and answer the questions that had been submitted and field any others that you guys might have. With that, Craig, I'll let you take it away and introduce everyone to DNA ID.
- Craig: Sure. All right. Thanks so much. As mentioned, I'm Craig Calderone, the CEO and founder of DNA ID. We are building a rare disease community marketplace for sharing genomic data, as well as patient-reported outcomes to help accelerate research and development into more pharmaceutical development and cures. From our end, we really started off by trying to identify a very clear-cut problem in the clinical trial recruitment phase. Overall, rare diseases are a pretty wide range inherently in the therapeutic space. 30% of those actually fail just to get patients actually involved in actual participating clinical trials and research studies overall. There's various different dropout points from all the different types of prescreening questions that might have to go into the actual development of the protocol for that. Plus, the consent to actually share their data, and then more screening, and more drop apps based on that.
- Craig: But overall, that process takes a pretty long time to do with a lot of actual fallout during that process. Really the rare disease patients, inherently being rare, are difficult to find, but are definitely out there. There's about 350 million people across the globe affected by some form of rare disease that's genetically inherited. It really does run in the family, but there are... Only about 95% of those rare diseases don't have an approved FDA treatment today. There's still a lot of headway that can be made in terms of really just getting more approved treatments through the FDA. But overall, 7,000 total rare diseases effecting a large population globally. That's, really a still right for opportunity in terms of just helping people out to, to help accelerate those, those treatments and research and cures.
- Craig: So that's where we come in. We are really building a faster solution for collecting patient data from the rare disease side. So they're really just connecting different data points from hospital systems, genetic labs, advocacy registries and trying to, to be that conduit to really pass that information on in, in a secure fashion to academic researchers that might, might need it, pharmaceutical labs that, need access to that data for, for their research purposes as well as individual precision medicine researchers that, may operate just solely based on grants and everything that as well. But we do build a mobile-first patient registry software, so advocacy groups can take up more control over their patient population data. But also, really giving that control back to the patient themselves and determine what happens with it after. So, collecting different data points from genomic data to healthcare records to survey questions of things that they actually experienced in everyday life and trying to put a more, a quicker feedback loop into that process so you can get more real world evidence out of that patient cohort as well.
- Craig: So, we are building that mobile solution that can take the research phase into the next level with DNA as a baseline. So many people out there are pretty familiar with DNA, direct-to-consumer DNA kits already and a lot of people ask what can you do with that information next? So, from there you can actually download a raw text

file that you can then use and various different types of services. But our solution is creating a way that you can more clearly determine what happens with that next and get paid, get researchers to actually pay you for access to that data as well. So really going off of more of the patient-centric ownership of that DNA and data overall. So really putting together more of a marketplace for folks to actually share their DNA data as well as survey data as well.

Craig: So, from our, we're operating as, as a business really depending on how many times you can actually allow the patients to share their data. Our unit economics are really in the rare disease space, about 50 patients per a rare disease trial. So, you know, typically larger clinical trials and research studies require a larger percentage of the population. But overall because rare disease trials individually affect a small population, it's a much shorter window that we can actually, give back to the clinical researchers to actually give them, more coherent actual patient records and really testing out the unit economic model there of what a patient could actually earn, what we could earn from helping them connect to those researchers that actually need it as well.

Craig: So, in terms of our go-to-market strategy as well, overall 7,000 rare diseases total and we broke that down into some of the rare disease drugs that are in development plus the focus of where we know that genetics and genomics can actually have a big impact on the actual research and development of those treatments. So, we started out by identifying their neurological types of advocacy groups, autoimmune groups as well as ophthalmology groups as well. So really putting together a target list of 59 different disease categories that we wanted to focus on and started to work with a lot of those advocacy groups in those individual disease categories as well.

Craig: So, in terms of just the, a quick client case study that we had, we helped the brain recovery projects. Which is a childhood epilepsy foundation for kids that had a hemispherectomy, which is half of their brain removed due to epileptic seizures that were drug resistant. So, we help them do more of the data analysis type of work on an existing registry that they had, were able to, really just in terms of how we found them more through social media, connecting on different Facebook groups and private forums, while still analyzing a large amount of patient volume. They had about 102, about 200 people in that, that registry. And we did an analysis for them on how they can really just best use that data. What's the actual demographics and, and cohort analysis of that entire group so that we can really just determine, what they can actually do with all of that, that cohort of patient data and then really give that back to the research community on a real world evidence level and help them go use that data more effectively as well.

Craig: So, in terms of the team that we put together, we do have a, a large software engineering background as well as some bioinformatics folks as well. I come from a background more in digital technologies having worked for Leanplum mobile marketing automation suite as well as, real time media analytics, Techstars and NASDAQ as well. So, we've put together a key advisory board with more experience in the actual industry, pharmaceutical industry, as well as academics and more of a data and science and engineering folks as well. So, and that's really the team that we put together and excited to keep adding to that team as well as we keep going forward. But in terms of how we're looking to that milestones are we're looking to achieve over the next year, we're really looking to bring more folks on board to help us with some of that product development and then obviously get people to actually shorten that feedback loop, increase sales and marketing, and growth efforts as well.

Craig: So, they're really trying to beat out a lot of those growth engines, but also trying to make sure that we build the software in a more streamlined enterprise type level as well. So, the way that we bundled a lot of our services together was really in three categories, really trying to optimize more for getting a lot of registries and advocacy groups that have access to patients on board. And really just breaking those down into a couple of different categories so that we can really help them use their data most effectively. But also, then keep the core mission intact to actually connect them and use that data for research purposes as well.

Craig: Just a couple of quick benefits to the actual researchers. We put together more of a data-centric storage and transfer technology. So, they're using some more cryptographic types of technologies there. We're able to really facilitate those things. So, it definitely removes us from the Phi types of considerations, but also ways that we can create different data pipelines for them to integrate into different services that they need to do statistical analysis on. Whether that is more of SAP-type tools or ours as is appropriate programming analysis tool as well. But really just hoping that we can actually help them effectively recruit patients more, which is something that they're not typically used to doing and does take a longer process for them to actually do.

Craig: And our advantage going forward is really just the, the core data that we can capture and community effort that we can put together from a mobile experience. So really putting together more of a comprehensive overview of the patient population. So really putting together a lot of key data points that affect people in real life but also

having a baseline of genomic data in there as well that we can then use to leverage to take accelerate a lot of the research and development out there as well. But we definitely have some big plans for the future just in terms of the technology that we're looking to build out, connecting with a lot of different electronic health records. It's a definitely a big undertaking for us, but definitely see Apple Health as leading the way that we can actually plug and play into those and make that a pretty seamless process.

Craig: Also, platform extensions really building out Android platforms as well as, keeping more engaged services. So, creating different types of marketplaces that people could use points or money for as well as just keeping people engaged using the overall product and keep coming back more than just once a year, which is typical and patient registries but really a more community led organization that they can actually keep coming back again and again. So that's pretty much it the deck perspective. It's definitely an exciting time from building DNA ID overall and excited to keep building it going forward.

Brett: Great. Thanks Craig. I just want to remind folks real quick before we jump into Q&A that if you do have questions we did have a couple people join late. You can go over to the Questions tab on the Control Panel and you could submit them there and we'll get into them. We've got a couple already, but just to, to start off on my end, and this may be just clarification for myself, but there may be some other folks that are out there that feel the same way. Is it, so you're connected, you have a platform that's connecting the advocacy groups or the patients who have the data to the researchers who need the data? And in most cases that you've seen so far, is it typically, who is the side of that marketplace that's coming to you looking to connect with the other? Is it more the researchers are saying like "Hey, you know, we really need a tool to go out there and find these advocacy groups in order to get this data?" Or is it the other way around?

Craig: It's more the other way around. So, a lot of the rare disease patients and advocacy groups are actively organizing their communities and are pretty active in trying to do something, and we're hoping to facilitate that transfer more. So, I think the harder side of the marketplace to get access to is the researchers. Typically, they work more off of grants and things that they don't necessarily have full access to that patient population. So, I think our are typically not used to doing that patient outreach. But I think trying to connect more with researchers is a little bit more difficult.

Brett: Got it. And then I was a little unclear on the business model side. So which side of that marketplace is paying you for the service?

Craig: So right now, it's the researchers that would be paying for the service. So, and the advocacy groups initially... So that the advocacy groups would pay us initially to host a patient registry for them. And then the researchers would be that business on the other side to connect with individual patients, pay them for their data, and then we would take a percentage of that transaction when that actually happens.

Brett: Got it. Makes sense. Okay. We've got a question here that says, "Why concentrate on rare diseases with hundreds of customers rather than non-rare diseases with millions of customers?"

Craig: So, the initial impetus there was to really focus on disease categories that have a genetic impact on it. Really focusing on how DNA can actually be used to accelerate the development there. It's really a starting point for us trying to get traction out initially to, as you saw before the average trial for a rare disease trial is about 50 patients. So, it's an easier target to get to as opposed to a trial or research project that needs hundreds of thousands or millions in order to be effective such as like heart disease or diabetes or some things like that. It's really just a smaller target that we can actually have a more focused effort on initially until we can then work on scaling that up from there.

Brett: Got it. I would imagine that, there's probably a lot more competition when it comes into the larger diseases.

Craig: Yeah, exactly. So, there's definitely a lot more folks that are focusing specifically on whether it is just diabetes or just heart attack or heart disease as well. So, if we can come from the other side of it and say like, "Hey, we have a ground-up grassroots type of technology that works for rare diseases. And now we have proved that out with a bunch of those different rare diseases and now we're ready to tackle the larger hundreds of thousands and millions of people that are involved in those. It's a different starting point for us.

Brett: And a quick question here about tractions. So, they're asking specifically how many customers are you currently working with and then revenue and what products, and I'm assuming this means which specific diseases are you focused on actively in the market currently?

Craig: So right now, we have three patient registries up and running. I'm working with two: one with epilepsy, two with muscular dystrophy. We're in talks with one other on the ophthalmology side to focus a little bit in on the connecting with different types of rare inherited blindness types of diseases as well and that we are looking into some of the, the advocacy groups around lupus, multiple sclerosis as well.

Brett: What are your thoughts around the people's... I'm sure you get questions like this, but if not, then certainly correct me, but around people's privacy and their data. Obviously DNA data is super personal, but I'm sure you guys have it, it's anonymous and so on, but what, what are your thoughts around the, and data privacy being a big topic these days, both in this space but also in even in kind of the social media space, do you guys get questions around that, any pushback around that and what are your thoughts on that, on that topic?

Craig: I mean that's definitely a core differentiator for us in terms of how we set up our storage infrastructure to...One, store the actual genomic information, but also how we set up permissions to actually share that data as well. So, we use that layer of, of storage technology that we don't necessarily have access to it unless the patient themselves gives us access to it. So, we're having a privacy-centric model up front by using that infrastructure layer to really facilitate that in a more privacy centric way. So, we can't use somebody's genetic information unless they give us access to it. And same way for research community as well. We're putting pretty granular permissions and privacy controls in place on that data storage so that the patient could determine how much do they want to share with whom and when they actually want to share it with them as well.

Brett: And then while we're on this, since you mentioned differentiator, we did have a question about competition. So, what do you see, I know we already touched a little bit on that some of the larger diseases have more competition, but who do you see as the main competitors and if there's any other points of differentiation outside of what you just shared on the data side? It'd be great if you could share some of that.

Craig: So, there's definitely a couple of different competitors out there that focus themselves on a couple of different areas. The more... Closest one that we have heard most in the market is a company called RDMD. They're focusing a lot on rare diseases but also on connecting more through desktop and through electronic health records where while we're focusing a little bit more, a lot more on the DNA side plus mobile focus as well. A few other ones that focus direct to consumer types of companies for kits, Nebula genomics, and backpack health. But I think from our perspective on how we differentiate with those folks is again, based on the DNA upfront. Well having that privacy layer built into it and then really just creating that engaging experience for people to keep coming back again and again to really just make that data more powerful from the patient themselves, but also how we can actually then facilitate the transfer to the research side as well.

Brett: Got it. And then, this you did talk on the use of funds. So, we had a question around that as well. I've only got a few more left. I'm trying to just check out on things that have already been answered. I guess, can you... There's questions about how the product may evolve in the future. I want to preface this with saying that there's no absolute statements we can say per Reg CF regulations about anything for looking. So, we can talk about plans for the future, but as long as everyone has the understandings that plans are always open to changing. But can you talk a little bit about how you see things? I think you already, you already touched on opening up into larger or going after larger markets or larger diseases, maybe some non-rare diseases, but how you see the product or service evolving as the company grows.

Craig: Yeah, for sure. So, I think right now we're definitely using more built on top of more an applied technology. Using different types of sequencing that people have gotten elsewhere. So, I think that as we evolve into doing that, there's a couple of different areas where we could move into potentially an area where we are the data creators as well. So, potentially selling direct to consumer kits ourselves, but focused on individual types of panels of rare diseases or different types of disease panels as well. I think also on the analysis piece, giving people a little bit more information about what their genome actually says and really evolving that process on information. I'm really giving a lot more information about someone's genome comparatively across to other different people in the cohort of their disease category.

Craig: I think that's a big thing that we're looking to get into is more of comparison types of approaches. So, based on I think how a disease progresses, the whole basis is a natural history of that study. So, a lot of rare diseases are inherently rare but also new. So, they don't necessarily always have a full picture of how that disease progresses. And I think if we can find a cohort of people and really put together more of a story of how that disease progresses over time, that's something that we hopefully be able to institutionalize a lot better through the platform.

- Brett: Got it. Sort of leading on that. Mentioned... Or I don't know if you had a chance to mention the, some of the community groups that you guys have built online and the reception around that. If you did mention that, maybe I missed it, but if not, maybe you can kind of recap some of the stuff you've seen there.
- Craig: So, I mean we're definitely focusing a lot of our efforts on where people are congregating initially. A lot of these things that are happening in Facebook groups that don't necessarily have the privacy-centric model. Giving Facebook your most private health information is not always the best idea. So, we wanted to take people off of those platforms, and really working with a couple of different groups around that. So, the brain recovery project we touched on a little bit, which is Epilepsy Foundation out of LA. Cureraredisease.org is one that's based out of Boston. That focus is on Duchenne muscular dystrophy. We have another Duchenne muscular dystrophy registry as well that's actually based out of Ukraine and are talking with an Applied's imaging EHR platform as well to potentially have an integration there for rare inherited blindness diseases as well, called unified imaging. So those are a couple of the organizations that we're working with already. And definitely looking to expand that more and more as we go.
- Brett: Got it. And then the last one that we had here was, it was again how to do with the use of funds and it was... And I'll kind of answer this for you, but just so we're getting a couple more coming in. Maybe we'll try to get one or two more of these. It was about the use of funds and the raise goal. So basically, if you didn't if you don't hit your mark, or the amount you're looking to raise then do investors get refunded? I believe there is a, a minimum and a maximum on this. In fact, I'm certain there is, and I think at the moment the minimum has been surpassed. So, assuming it's, we ended up closing on that, the amount that we close on, we'll go to the company.
- Brett: So that's the investment will still be made and then the use of funds will be broken out depending on what that final number is. And if... I'll remind folks at the end, but if you want to get an understanding of that use of funds, Craig went through it in the deck, but we also have a little bit more detail on the campaign page and the microventures.com website. If you go to the DNA ID page under the Invest tab, you can see there's scroll down, you can see there's kind of two scenarios broken out based on the minimum and the maximum. And, and you can get more information there. While I was speaking, we had a couple other questions come in. The sales cycle. Can you talk a little bit about what that looks like at the moment?
- Craig: So, the, the sales cycle initially is a little bit longer until we can kind of optimize that process. But right now, it's anywhere between 90 days to six months. So, I'm really getting a patient registry up and running depending on their sophistication, whether they have an existing one, don't have any at all, or we're replacing one. And then based on that criteria the sales cycle can get shorter or longer depending on that. But we're definitely having a pipeline, sales pipeline that will be built out to hopefully identify a lot of that process and where we could make sure that we're optimizing a lot of that as well. But that's what we've seen so far.
- Brett: And if I understand correctly, it seems like most of the stuff you're doing so far is sort of customized solutions for your customers where part of the funds that you're raising will go towards making it a little bit more so, I don't know if self serves the right word but a more streamlined.
- Craig: Definitely a fair point. Right now, it is in the beginning, trying to do a lot of handholding on creating some of the custom solutions. But as we can definitely like module-ize a lot of the software technology then it definitely becomes a lot more automated and self-service as well.
- Brett: Great. And the last couple of questions we have, which we're not going to answer here, but I want to just address them are about the terms of the security that's being offered to investors. We... Similar to the use of funds, I would encourage you to go to microventures.com and then hit the Invest tab and find the DNA ID campaign page. There you can see all of the terms are spelled out. I can't go over them on the webinar today, but you can see them there. And then there's also a discussion forum down at the bottom, so if you have any questions you can submit questions there. A good portion of people who will be listening to this will be listening to the recording after the fact. So, in addition to the information that we have on there, you can submit questions through that discussion forum.
- Brett: And then lastly, for folks who are interested in participating in this from an investment perspective, if you go to that same page, we've got a bright orange Invest button up in the top right and you can click there and if you don't have an account, make one and we should be able to walk through the process and make an investment. So, I believe that's going to be it for us today. Craig, before we sign off, is there any kind of final words you'd like to share with folks or anywhere else you'd like to point people?

Craig: No, I think if there isn't definitely any other questions about the company definitely feel free to check out the website as well, DNAID.co. And excited to get moving on, building a lot of the future technology that we covered today and are excited to help more people connect with the right research communities that can definitely accelerate some of the treatments and cures for them as well.

Brett: Sounds great. Well, I appreciate it, Craig. Thank you to everyone who joined in to listen to this live and ask questions. We really appreciate it. And to anyone who's listening to the recording after the fact. Thanks for checking this out and Craig. Thanks again, and thanks for the time and thanks for the great presentation.

Craig: Thank you very much. Take care. You have a good one.

Brett: Bye.